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ABSTRACT 
 
 
 Most vaccines used nowadays are created using inactivated or attenuated compounds 
from micro-organisms. Advances in basic immunology and molecular biology opened the 
gate for consequent improvement of vaccination strategies. The vast majority of successful 
vaccines developed so far functions through production of specific antibodies, thus allowing 
rapid eradication of the disease’s causative agent. However, intracellular bacterial pathogens 
like Mycobacterium tuberculosis hide from immune attack by antibodies within cells, and 
their virulence is related to their capacity to survive for prolonged times within macrophage 
phagosomes by blocking lysosomal delivery and subsequent degradation. Therefore, design 
of more effective vaccination strategies is needed to ensure efficient killing of this type of 
pathogens. The discovery of CD1 molecules, that present lipidic antigens from the bacterial 
cell wall to T cells, might be an additional step in this direction. In this dissertation, we used 
chemical and biochemical approaches to identify and synthesize lipid antigens, as well as T 
cell activation assays, molecular biology tools, and transgenic mice to evaluate the potential 
of lipid antigens to be included in subunit vaccines. 
In a first series of studies, we identified glycerol monomycolate (GroMM) as a mycobacterial 
lipid antigen that activates CD1b-restricted T cells, and confirmed its immunogenicity during 
the course of infection by M. tuberculosis. GroMM efficiently stimulates T cells from PPD-
positive healthy donors, but not from non-infected donors nor patients with active 
tuberculosis. These data suggest that GroMM-reactive T cells are primed during infection and 
may contribute to protection against pathogenic mycobacteria, rendering GroMM an 
interesting candidate for further evaluation to be used in vaccination strategies. 
A second series of studies dealt with a lipid antigen from M. tuberculosis previously 
identified in our laboratory, i.e. diacylated sulfoglycolipids (Ac2SGL). Sulfoglycolipid (SGL) 
analogs were synthesized in order to study the structural constraints governing binding to 
CD1b and generation of immunogenic CD1b-SGL complexes. Comparison of these analogs 
sharing the same trehalose-sulfate polar head but differing in the structure of their acyl tails 
showed that the number of C-methyl substituents, the configuration of the chiral centers, and 
the respective localization of the two different acyl chains on the polar head are important 
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structural elements that must be considered for the design of sulfoglycolipid analogs with 
potential use as vaccine subunits. 
In a third series of experiments, we began pre-clinical in vivo studies in CD1b-transgenic 
mice that we have generated, using the most immunogenic synthetic SGL analog. CD1b:SGL 
dimers allowed us to follow successful priming and expansion of CD1b-restricted SGL-
reactive T cells after immunization. Finally, we have investigated different ways to increase 
immunogenicity by facilitating lipid solubilisation and transport into antigen presenting cells 
(APCs). 
Altogether, the data obtained and discussed in the present dissertation go through the first 
stages of a vaccine’s development, from identification of candidate antigens to pre-clinical in 
vivo studies in mice. Confirmation of the protective effect of the lipid antigens described 
herein will determine whether they can be considered as candidate compounds of a subunit 
vaccine. 
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INTRODUCTION 
 
 
 Genetic history of CD1 and MHC molecules 
 
 The MHC locus is present in the genomes of all mammals and is spanning over 3,600 
kb of chromosome 6 in humans with 128 functional genes and 96 pseudogenes [1, 2]. Many 
of these genes are directly involved in various aspects of the adaptive immune system, but 
there are others involved in innate immunity and some that have functions completely 
unrelated to the immune system [3]. The MHC locus is itself part of linear array genes on 
chromosome 6 in humans that is at least partially duplicated on three other chromosomes in 
most jawed vertebrates [3-5]. These four paralogous regions located on chromosomes 1, 6, 9, 
and 19 in humans are collectively referred to as the MHC paralogy group.  
To fully appreciate the evolutionary history of the MHC, we must return to the sea. The sea 
lancet, or amphioxus, is a cephalochordate that is thought to represent a critical transitional 
form that eventually led to the emergence of true vertebrates [6]. Amphioxus possess a locus 
of genes referred to as the proto-MHC. These proto-MHC genes are quadruplicated on four 
different chromosomes in jawed vertebrates, thus forming the core gene set of the MHC 
paralogy group. The homologs of the proto-MHC genes are found within the present-day 
mammalian MHC locus, and it is this cluster of genes that is thought to be the primordial 
genomic scaffold on which MHC I, MHC II, and other members of the MHC-based adaptive 
immune system later evolved. It is estimated that a duplication of the proto-MHC occurred 
approximately 600 million years ago in an early jawless vertebrate ancestor after splitting of 
from the cephalochordate lineage [4, 7, 8]. A second duplication is thought to have occurred 
in an early jawed vertebrate ancestor after splitting off from the jawless vertebrate lineage [9, 
10]. This ancestral species subsequently gave rise to all jawed vertebrates, carrying with it the 
four paralogous copies of the proto-MHC found today, one of which forms the core of the 
actual MHC locus. Whether two rounds of genome duplication took place, or a single round 
plus extensive localized segmental duplications, is still a matter of debate. 
However, the precise genetic progenitor of MHC I and MHC II antigen presentation 
molecules remains a mystery. Several theories have been proposed to explain how these 
genes may have initially evolved [11]. 
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The CD1 human locus was discovered in 1979 [12], whereas the antigen-presenting function 
of CD1 molecules has been highlighted in the early 90’s [13]. The hypothesis that CD1 and 
MHC I antigen presentation molecules share a common ancestry is strongly supported by 
sequence alignments and structural data. But the precise age of CD1 relative to MHC I has 
remained unresolved. Bearing in mind that the collection of genomic sequence data from 
lower vertebrates is still ongoing, the data examined so far suggests that CD1 may be more 
recent than MHC I. Evidence of CD1 homologs in both birds and mammals implies that a 
primordial CD1 gene was present in the common ancestor of both groups. The separation of 
birds and mammals from a common reptilian ancestor into two distinct lineages is one of the 
major milestones in vertebrate evolution: the Synapsid-Diapsid (S-D) split. Mammals 
emerged from the Synapsid lineage while birds derive from the Diapsid [14]. Fossil evidence 
led to the conclusion that the divergence between Synapsid and Diapsid lineages occurred 
approximately 310 million years ago [14, 15]. Thus, the age of CD1 gene family can be 
pushed back to before the existence of true mammals. Molecular clock analysis calculations 
evaluated the separation of MHC I and CD1 at approximately 384 million years ago [16]. 
This timing corresponds closely with the appearance of the first tetrapods in the Devonian 
fossil record roughly 365-385 million years ago [17]. These data suggest that the emergence 
of CD1 in the vertebrate genome occurred in the reptiliform lineage after the amphibian-
reptile split, close to the water-to-land transition. 
The clear homology between MHC I and CD1 using both the amino acid sequence alignment 
and crystal structure data suggests that CD1 arose by gene duplication of a primordial MHC 
I. The human CD1 locus is located on chromosome 1 and is therefore unlinked to the MHC 
locus on chromosome 6 [18]. The CD1 gene(s) likely translocated from a primordial MHC 
locus in an early mammalian ancestor after the bird-mammal split 310 million years ago. 
Selective pressure has been proposed as an explanation [19]. 
The human CD1 gene family is composed of five nonpolymorphic genes (CD1A, -B, -C, -D, 
and -E). It seems that the CD1 family of genes arose in an early mammalian ancestor, prior to 
the initial diversification of mammals around 125 million years ago in the Cretaceous period 
[20-22].  
The MHC I requires a complex network of accessory molecules for effective presentation of 
peptides [23]. It seems that at least a subset of CD1 lipid antigens do not require 
internalization or processing to bind CD1 for subsequent recognition by T cells. These short-
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chain lipid and glycolipid antigens can be loaded directly onto fixed APC for recognition by 
T cells [24-28]. Therefore, an early CD1 isoform would not necessarily require specialized 
molecules for antigen acquisition, internalization, processing, loading, or even the need for 
deep intracellular trafficking [25]. The initial evolutionary divergence of CD1 would 
therefore not be constrained by the need for specialized accessory proteins. However, lipid 
binding proteins and transport molecules, like saposins and ApoE [29, 30], that are not 
strictly CD1-specific but also have alternative physiological roles, may, to a certain extend, 
be considered as accessory molecules. Thus, it is also possible that the existence of any or all 
CD1 accessory molecules preceded the emergence of CD1. The transition from a single CD1 
gene to an extended gene family probably occurred by duplication and neofunctionalization 
in a manner similar to other multigene families, including MHC I itself. Each of the CD1 
isoforms has evolved a slightly different intracellular pattern of traffic and it has been 
postulated that this allows the CD1 proteins to broadly survey the intracellular environment 
of an APC for potential lipid antigens [26, 31, 32]. 
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 Structure of CD1 proteins 
 
 Although CD1 molecules are found in all mammalian species studied to date, the 
following data will focus only on human and mouse CD1 for which crystal structures are 
publicly available. The human CD1 antigen-presenting molecules were originally classified 
in group 1 (CD1a, CD1b, and CD1c) or group 2 (CD1d), while only CD1d is expressed in 
mice [20]. CD1e does not present lipids to T cells because it is not detectable on the cell 
surface, but it participates in intracellular lipid processing and subsequent loading onto other 
CD1 family members within endosomes. This is why CD1e is considered as a third group of 
CD1 molecules [33, 34]. CD1 are expressed as glycosylated proteins and are structurally 
similar to their peptide-presenting, MHC class I analogs. CD1 molecules form a stable, 
noncovalently associated heterodimer with beta 2-microglobulin (β2m) of approximately 49 
kDa, including N-linked carbohydrates. Like MHC class I, the ectodomain, or CD1 heavy 
chain, is organized into three domains, α1, α2 and α3, and is anchored in the cell membrane 
by a transmembrane domain. The α1 and α2 domains combine to form the central binding 
groove of each CD1 isotype and differ from one another in primary amino acid sequence and 
three-dimensional structure, whereas the α3-domain is highly conserved among all isotypes 
and associates with β2m. A tyrosine-based sorting motif, composed of tyrosine, two spacer 
amino acids, plus a hydrophobic amino acid (YXXZ), is encoded on the short cytoplasmic 
tail of CD1b, CD1c and CD1d to which adaptor proteins bind, but is absent in human CD1a 
[35]. This motif is directly responsible for the difference of sorting between the CD1 
isoforms, CD1b-d recycling into late endosomal compartments [26, 27, 35, 36], whereas 
CD1a recycles into early endosomes [37]. 
The CD1 binding grooves are composed of two main pockets, named A’ and F’, and are 
found in CD1a, CD1b and CD1d [38]. CD1b has an additional C’ pocket and T’ tunnel [39]. 
The central binding groove is formed by two anti-parallel α-helices (α1 and α2), which sit on 
top of a six-stranded β-sheet platform. The groove is deeper and narrower than the cleft 
observed for binding peptides in classical MHC class I or II [40]. The overall three-
dimensional structures of individual members of the CD1 family are similar to one another, 
but amino acid substitutions in the α1-α2 superdomain are responsible for shaping the 
individual grooves and for the formation of isotype-specific pockets. The pockets and tunnels 
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are hydrophobic and accommodate the lipid backbone of all CD1 antigens. The carbohydrate 
or peptide headgroups are exposed at the cell surface and serve as the major T cell epitopes. 
 
  CD1a 
 
 CD1a has the smallest of the binding groove with a volume of ~1,350 Å3, which 
allows about 36 carbon atoms to fit into [41]. CD1a has an unusual A’ and F’ pocket 
structure compared to the other isoforms (Figure 1). The A’ pocket is not directly connected 
to the CD1 surface and is only accessible through the more exposed F’ pocket. The CD1a 
groove can be described as a long tube that terminates at the end of the A’ pocket and has its 
only entrance through the F’ pocket. This means that the length of any alkyl chain that can be 
inserted into the A’ pocket is restricted by this unique, blunt-ended pocket and is predicted to 
correspond to approximately C16.  
 
 
Figure 1: Two-dimentional schematic rendering of CD1a groove and its constituent A’ and 
F’ pockets, drawn based on the silhouette of the crystal structure of human CD1a. 
Interdomain contacts between the α1-helix and α2-helix close the top of the A’ pocket, so that 
ligands enter the groove through the F’ portal. In yellow is the β2m. 
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  CD1b 
 
 Human CD1b has the largest binding groove (~2,200 Å3) among the CD1 proteins 
described to date. Thus, CD1b can bind the largest of the CD1 antigens, including long chain 
fatty acids up to approximately C80. The binding groove is composed of four interconnected 
pockets (A’, C’, F’, and T’) [39] (Figure 2). CD1b has a C’ pocket that originates near the 
junction of the A’ and F’ pockets, descends into the groove and connects directly to the outer 
surface of CD1b via a structure known as the C’ portal, which is located distal to the TCR 
interaction surface. This second connection between the interior of the groove and the outer 
surface of CD1 might allow egress of alkyl chains that exceed the capacity of the C’ pocket, 
which corresponds approximately to C16. 
 
 
Figure 2: Two-dimentional schematic rendering of CD1b groove and its constituent A’, C’, 
F’ and T’ pockets, drawn based on the silhouette of the crystal structure of human CD1b. 
Interdomain contacts between the α1-helix and α2-helix close the top of the A’ pocket, so that 
ligands enter the groove through the F’ portal. Human CD1b has a second entrance and/or 
exit at the bottom of the C’ pocket, known as the C’ portal. In yellow is the β2m. 
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  CD1c 
 
 No crystal structure of CD1c is available yet. Information about its structure is 
inferred from amino acid sequence similarities with other CD1 proteins and the chemical 
structures of the antigens it presents. It seems that the individual pockets of the CD1c binding 
groove are unlikely to be as narrow as the A’ pocket of CD1a, but instead will have a slightly 
greater diameter or multiple side pockets to accommodate the methyl groups from the 
antigens alkyl chains [40]. Sequence alignments with other CD1 isotypes suggest that CD1c 
is likely to have an open-ended A’ pocket, like CD1b. The presence of an alternate exit 
portal, like the C’ portal of CD1b, is also a possibility. However, no T’ tunnel is predicted for 
CD1c, and it may also lack a C’ pocket. 
 
  CD1d 
 
 The first crystal structure of mouse CD1d was obtained in 1997 and described only 
the two A’ and F’ pockets [38] (Figure 3). The binding groove of mouse CD1d has an 
approximate volume of ~1,650 Å3 [40]. Empty binding grooves have not been observed for 
mouse CD1d that comes from natively folded protein, so it seems plausible that a pocket-
stabilizing factor is bound until it is replaced with another antigen during its trafficking 
through various intracellular compartments. More recent structures of human and mouse 
CD1d revealed a complex hydrogen-bonding network responsible for the orientation and the 
high affinity binding of lipid antigens inside the groove [42-47]. 
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Figure 3: Two-dimentional schematic rendering of mCD1d groove and its constituent A’ and 
F’ pockets, drawn based on the silhouette of the crystal structure of mouse CD1d. 
Interdomain contacts between the α1-helix and α2-helix close the top of the A’ pocket, so that 
ligands enter the groove through the F’ portal. In yellow is the β2m. 
 
  CD1e 
 
 No crystal structure of CD1e is available yet. Like other CD1 molecules, CD1e is 
noncovalently associated with β2m. However, its α-chain is cleaved between the α3 and the 
transmembrane domain in late endosomal compartments, generating by this way soluble 
CD1e, which represents the CD1e active form [33, 34]. A recent model suggests that CD1e 
binds glycolipids in a central cavity, similar to the binding of other CD1 members [34]. 
 
 Structures of ternary CD1-lipid-TCR complexes 
 
 The CD1-lipid complexes interact with TCR αβ, but crystal structures of ternary 
CD1-lipid-TCR complexes are not available yet for group 1 CD1 molecules. Models of 
CD1a-lipopeptide-TCR and CD1b-mycolic acid-TCR exist, and suggest that the TCR adopts 
a diagonal positioning similar to MHC-TCR complexes [48, 49]. The crystal structure of the 
ternary complex hCD1d-αGalCer-TCR (Vα24-Jα18, Vβ11) has recently been solved and 
determined to 3.2 Å resolution (Figure 4) [50]. The iNKT TCR bound approximately parallel 
to the long axis of the CD1d-antigen-binding cleft, which is distinct from the broad range of 
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“diagonal” footprints observed for MHC class I-restricted TCRs. The total buried surface 
area of binding between the iNKT TCR and CD1d is approximately 910 Å, below the range 
observed at the TCR-peptide-MHC interface [51]. The α-chain contributes more per cent of 
the buried surface area than the β-chain (65.5% versus 34.5%, respectively). The iNKT TCR 
α-chain interactions are mediated only by the complementarity-determining region (CDR3)α 
and CDR1α loops. The CDR1α loop interacts solely with the αGalCer, whereas the 
CDR3α loop straddles the antigen-binding cleft, interacting with the α1-helix, the α2-helix 
and αGalCer. αGalCer protrudes minimally from the CD1d cleft with only the glycosyl head 
exposed for recognition by the iNKT TCR, interacting solely with the CDR1α and 
CDR3α loops. The plasticity of the iNKT TCR regarding other ligands is attributed to the 
CDR3β loop, that contributes only 6% of the buried surface area. The CDR2β loop 
contributes 27.5% of the buried surface area, contacts CD1d, and seems to have an important 
role, although yet undefined, in enabling a CD1d-restricted response. 
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Figure 4: Overview of the human CD1d-αGalCer-iNKT TCR ternary complex. hCD1d 
heterodimer is on the bottom; αGalCer is in the middle; iNKT TCR α-chain and β-chain are 
on the top. The β2m is behind the CD1d molecule. 
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 CD1 expression patterns 
 
 Group 1 CD1 molecules are almost exclusively found on professional antigen 
presenting cells (APCs) and thymocytes. They are expressed on double positive (CD4+CD8+) 
cortical thymocytes and with less intensity on CD4+ and CD8+ single positive thymocytes 
[52]. 
CD1a is expressed on Langerhans cells (LCs) [53]; on peripheral dendritic cells (DCs) [54]; 
on DCs differentiated from CD14+ monocytes with interleukin-4 (IL-4) and granulocyte-
monocyte colony stimulating factor (GM-CSF) when cultured with fetal calf serum (FCS) 
[13, 55-58]; on DCs differentiated from CD34+ hematopoietic progenitor cells by culture 
with GM-CSF and tumor necrosis factor (TNF) [59-61]; and on mature DCs [62, 63]. Recent 
data indicate that CD1a surface expression is stabilized by serum lipids [24]. 
CD1b is expressed on the very same types of DCs than CD1a (see references above), except 
Langerhans cells. In addition , CD1b is expressed also on dermal and lymph node 
interdigitating DCs [64]. CD1b expression has also been found on perivascular inflammatory 
cells and hypertrophic astrocytes of chronic-active MS lesions, whereas its expression in 
chronic-silent multiple sclerosis (MS) lesions is limited to a few perivascular astrocytic foot 
processes and occasional macrophages [65]. These data suggest a specific role for CD1b in 
the active disease. 
CD1c is also expressed on the same types of DCs than CD1a (see references above) and on 
Langerhans cells [53]; but also on dermal and lymph node interdigitating DCs [64]; on a 
subpopulation of circulating peripheral B cells [54, 66]; in lymph node mantle zones and 
germinal centers [64, 67, 68]; and on marginal zone B cells in the spleen [67]. CD1c can be 
induced by B cell activation, and has been proposed as a marker for distinguishing B cell 
populations, in particular mantle zone B cells [69]. 
CD1b and CD1c expression on the surface of DCs do not change during maturation, but 
CD1a expression decreases slightly [62, 63]. It should also be pointed out that infection with 
M. tuberculosis upregulates CD1a, CD1b and CD1c expression in CD1- myeloid precursors 
[70]. CD1a, CD1b and CD1c expression is also induced on dermal granulomas DCs of 
patients with tuberculoid form of leprosy, being associated with active cellular immunity, but 
not with the lepromatous form, suggesting that downregulation of CD1 molecules might 
constitute an immune evasion strategy [71]. CD1a and CD1c have also been reported on DCs 
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in the inflamed synovium of rheumatoid arthritis [72]. In human breast cancer, tumor-
infiltrating CD1-positive DCs have been reported, and their presence correlated with 
prognosis [73, 74]. In a cutaneous T cell lymphoma named mycosis fungoides, CD1b and 
CD1c expression is increased [75], whereas CD1c is downregulated in B chronic 
lymphocytic leukemia [76]. Recently, the beta herpes virus human cytomegalovirus has been 
shown to inhibit transcription and to block cell surface localization of group 1 CD1 
molecules [77]. 
Here must be pointed out that group 1 CD1 molecules are not expressed on the surface of 
macrophages, rendering cross-priming and subsequent presentation by DCs essential in the 
case of infection by intracellular pathogens like M. tuberculosis. 
In peripheral blood, human (h) CD1d is expressed on B cells, monocytes and activated T 
cells [78]. Cortical thymocytes also express hCD1d, but its expression is downregulated in 
medullary thymocytes and absent on naïve peripheral T cells. However hCD1d is re-
expressed upon activation of peripheral T cells [79, 80]. It is also present on monocyte-
derived macrophages and DCs, and dermal DCs [81, 82]. In the lymph node, hCD1d is 
expressed on DCs in the paracortical T cell zones and on mantle zone B cells, but not on any 
cells of the germinal center [78, 83]. It has also been detected in epithelial cells of the small 
bowel and colon [84], as well as on hepatocytes, bile duct epithelium, pancreas, kidney, 
endometrium, testis, epididymis, conjunctiva, breast, skin, tonsils, and vascular smooth 
muscle cells [85]. In the skin, hCD1d is found on keratinocytes, endothelium, eccrine ducts, 
acrosyringium, and the pilocebaceous unit except for dermal papillae and hair matrix cells 
[86]. hCD1d is also expressed in anagen phase growing hair [87]; in spindle-shaped cells 
found under the oral epithelium in noninflamed sections of periodontal biopsies [88]; and on 
trophoblast cells [89]. 
Several isoforms of hCD1d have been described [78, 89-93], with a certain degree of tissue-
specificity and differences in glycosylation. Also, regulation of hCD1d is dependent on cell 
type-specific factors [94]. It should also be noticed that hCD1d is more abundantly expressed 
on the colonic epithelium of patients with inflammatory bowel disease [85], as well as in the 
affected tissues of patients suffering of Crohn’s disease and ulcerative colitis [95]. Several 
liver diseases involve alterations in hCD1d expression as well [85, 96, 97]. hCD1d is also 
expressed in epithelioid granuloma cells in both primary biliary cirrhosis and sarcoidosis. 
Primary biliary cirrhosis patients express hCD1d on epithelial cells of the small bile duct 
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[98], and upregulation is important on hepatocytes infected with hepatitis C virus [99]. Other 
diseases influenced by hCD1d upregulation include psoriasis [85, 86] and experimental 
autoimmune encephalomyelitis [100]. Many tumors express hCD1d, including acute myeloid 
leukemias, juvenile myelomonocytic leukemias, acute lymphoblastic leukemias, B cell 
chronic lymphocytic leukemias, gliomas and brain tumor vasculature, and cutaneous T cell 
lymphomas [101-105]. 
Mouse (m) CD1d is expressed in thymus, lymph node, liver, stomach epithelium, small 
intestine and colon [96]. mCD1d is present in all fetal organs but only in thymus, spleen, liver 
and lung of adult mice [106]. It is also expressed on T cells, B cells, macrophages and 
hepatocytes [107]; on bone marrow cells, DCs , and intraepithelial lymphocytes [108]. 
Further analysis of the mouse hematopoietic compartment identified mCD1d expression in 
multiple lineages, including B cells, T cells, macrophages, CD11c+ DCs, thymocytes, thymic 
stromal cells, and thymic DCs [109, 110]. High mCD1d expression is also detected on 
splenic marginal zone B cells [109, 111, 112]. It is also present on endometrial endothelial 
cells of the cervix and fallopian tubes [113]; and on collecting ducts and blood vessels of the 
pancreas [114]. 
The mouse genome contains two CD1 genes, CD1d1.1 and CD1d1.2, which are 95% 
identical. They are equally expressed in the thymus, but CD1d1.1 is the predominant 
transcript in other tissues [115]. It seems that mouse CD1 mRNA levels correlate with 
surface protein expression, indicating that transcriptional regulation might modulate surface 
concentrations of mCD1d [116]. These two mCD1d isoforms may have close functions, but 
CD1d1.2 seems to play little role in vivo [117]. Variants with different glycosylation also 
exist for mCD1d [106]. 
In contrast to the regulation of group 1 CD1 proteins, surface levels of human and mouse 
CD1d remain quite constant over a wide range of experimental conditions [78, 108], even if 
they have a tendency to be upregulated upon infection with Leishmania infantum and 
mycobacteria [118, 119]. However, CD1d surface level has been shown to be downregulated 
by certain viruses, primarily through increased internalization [120, 121], probably reflecting 
immunoevasion strategies. As for CD1b and CD1c molecules, T cell recognition can also be 
altered via impairment of CD1d lysosomal trafficking, preventing binding of its dedicated 
lipid antigens [122]. 
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Rat CD1d has similar tissue distribution to that seen in mouse, plus expression in heart, 
kidney and lung [123]; and on intestinal villi of enterocytes [124]. 
Thus, the wide tissue distribution of CD1d and its location on many parenchymal and 
endothelial cells differs markedly from the group 1 CD1 proteins. Expression of group 1 and 
group 2 CD1 molecules has also been demonstrated in CD68+ lipid-laden foam cells in 
atherosclerotic lesions, but not in normal arterial specimens [125]. In autoimmune thyroiditis, 
CD1 bearing DCs and CD1c-positive B cells were detected in inflamed thyroid tissues [68]. 
CD1e localizes to the Golgi of immature DCs, then in the lysosomes upon maturation, where 
it is cleaved into a soluble form [126]. Its strict intracellular localization excludes any direct 
interaction with T cells, but CD1e is required for lysosomal degradation of 
phosphatidylinositol mannoside (PIM)6 and subsequent activation of CD1b-restricted T cells 
[34]. Here must be pointed out that a naturally occurring mutation in CD1e has recently been 
shown to prevent its correct assembly and transport to late endosomal compartments, thus 
being directly responsible for an altered immune response to complex glycolipid antigens 
[127]. Splicing variants have also been described for CD1a, CD1c, and CD1e molecules [33, 
128], but their precise characterization is still unclear. 
 
 CD1 assembly 
 
 CD1 assembly and N-glycosylation takes place in the endoplasmic reticulum (ER) 
(Figure 5). CD1 molecules utilize some of the same chaperones as do MHC class I 
molecules, but CD1 folding and assembly reveal subtle differences. Calnexin and calreticulin 
are ER chaperones that bind β2m-free CD1d heavy chains, but not β2m-bound (on the 
contrary to MHC class I molecules), and disulfide bond formation is mediated by the 
associated ERp57 [129]. The fully oxidized CD1d heavy chains dissociate from these 
chaperones, and the majority of CD1d heavy chains then bind β2m before exiting the ER. A 
small fraction of CD1d heavy chains is also able to exit the ER without association with β2m 
and reach the plasma membrane [91, 130]. 
The exit of MHC class I molecules from the ER requires occupation of their peptide-binding 
groove with proteasome-derived peptides that are translocated into the ER by the transporter 
associated with antigen processing (TAP) [131, 132]. Similarly, the peptide-binding groove 
of MHC class II molecules is occupied through its association with invariant chain, which 
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also serves to target the multimeric complex to the endocytic system [131]. In the case of 
CD1 molecules, they acquire self lipid ligands in the ER, which influences their surface 
expression and antigen presentation function. Nascent CD1d associates with 
phosphatidylcholine (PC) [45], maybe also with spacer molecules [43], as do CD1b [133]. 
Phosphatidylinositol-containing compounds including glycosylphosphatidyl inositol (GPI) 
were eluted from CD1d molecules expressed in TAP-deficient cells [134], and PI was 
detected in association with a soluble form of CD1d containing the KDEL ER retention 
signal [135]. GPI and PI abundant expression in the ER suggest that assembly of CD1d with 
cellular phospholipids occurs in this compartment [136]. Microsomal triglyceride transfer 
protein (MTP) is an ER-resident lipid transfer protein (LTP) that has been proposed to be 
critical for proper assembly and antigen presentation function of CD1d, probably via transfer 
of lipids onto CD1d [137-139]. Recently, MTP has also been shown to be involved in the 
functioning of group 1 CD1 molecules, by regulating both endogenous and endosomally-
loaded exogenous lipid antigen presentation [140]. 
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Figure 5: Assembly and intracellular trafficking of CD1 molecules. Assembly of CD1 
molecules takes place in the ER with the help of chaperones named calnexin, calreticulin, and 
ERp57. CD1 associate noncovalently with β2m, then traffic to the Golgi and the plasma 
membrane. A fraction of CD1 molecules associates with the invariant chain (Ii) which 
promotes trafficking to late endosomal compartments. Surfaces CD1b-d molecules are 
internalized in clathrin-coated pits, associate with AP-2, and move to sorting endosomes. 
There, they move to late endosomes/lysosomes upon AP-3 binding. CD1a recycles only in 
early endosomes. 
 
 CD1 trafficking 
 
 After assembly in the ER, the majority of CD1 molecules follow a secretory route via 
the Golgi where N-glycosylation is achieved and traffic directly to the plasma membrane 
[141]. Once on the plasma membrane, the CD1 molecules can be internalized and enter the 
endocytic pathway (Figure 5). It seems that the cytoplasmic tails of CD1 play a primary role 
in their trafficking to intracellular compartments [36, 141-143]. The cytoplasmic tails of 
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CD1b, CD1c, hCD1d and mCD1d contain a tyrosine-based sorting motif that bind the 
adaptor protein complex-2 (AP-2) at the plasma membrane, which allows sorting of CD1 and 
other transmembrane cargo proteins into clathrin-coated pits [142, 144]. CD1b internalization 
is also mediated by dynamin [141], which is thought to be involved in membrane fission. 
CD1a does not contain any apparent sorting motifs in its cytoplasmic tail, but was found in 
clathrin-coated pits and clathrin-coated vesicles in in vitro-derived DCs and freshly isolated 
LCs, a type of DCs resident in the epidermis [27, 37]. CD1a can also be internalized in a 
clathrin- and dynamin-independent manner, and it follows a Rab22a- and ARF6-dependent 
recycling pathway in HeLa cells, similarly to other cargo internalized independently of 
clathrin [145]. Ii has recently been found in association with CD1a at the cell surface of 
immature DCs and proposed to be a key regulator of its surface expression, as Ii silencing 
induces CD1a accumulation at the cell surface [146]. 
After internalization, both CD1a and CD1c molecules have been shown to traffic to early 
recycling endosomes and co-localize with early recycling compartment markers [27, 37, 
144], where CD1b is almost absent [27]. 
CD1b and mCD1d molecules recycle in late endosomal/lysosomal compartments. In the case 
of CD1b, a role for the adaptor protein complex-3 (AP-3) in its recycling has been proposed 
[147]. CD1c is also present in the lysosomes [63], but does not bind to AP-3 [147], 
suggesting that an AP-3 independent pathway for CD1 trafficking to lysosomal 
compartments also exists [144]. mCD1d trafficking to lysosomes has been proposed to be 
mediated by AP-3 [143, 148, 149], but also by association with the MHC class II-Ii complex 
[129]. 
CD1e trafficking is different from other CD1 molecules, as it is not present on the plasma 
membrane, and maturation of DCs modify its localization [126]. In immature DCs, 
membrane-bound CD1e stays in the Golgi, and traffics to late endosomal compartments upon 
maturation where it is cleaved and becomes soluble [33, 34]. The cytoplasmic domain of 
CD1e consists of 53 to 61 amino acids, and does not contain any specific targeting motif, but 
is essential to intracellular retention and Golgi accumulation of CD1e [150]. Its traffic to 
LE/lysosomes seems to be facilitated by ubiquitination of the cytoplasmic domain, a 
phenomenon increased upon DCs maturation [150]. 
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Structure, biology and functions of Lipid Antigens 
 
 To discuss lipid antigens, a first distinction between T cells has to be made. Indeed, 
antigens presented by CD1d molecules are recognized by T cells that express a semi-
invariant TCR (Vα24-Jα18 and variable Vβ11 chains in humans, Vα14-Jα18 and Vβ8.2, 
Vβ7 or Vβ2 chains in mice). This type of T cells also expresses markers characteristic of 
natural killer cells, and is therefore named invariant (i) NKT cells. Antigens presented by 
group 1 CD1 molecules (and in some cases also CD1d) are recognized by T cells expressing 
a variety of TCR heterodimers, apparently without bias for unique V or J genes. Human 
CD1-restricted T cells may express CD4, CD8, or are CD4 and CD8 double-negative. Initial 
studies have shown that lipid-specific T cells can easily be detected in the circulating blood 
[151, 152], even at frequencies close to classical MHC-restricted and peptide-specific T cells 
[153]. 
 
  Self Lipid Antigens 
 
 Self lipids that stimulate T cells can be subdivided into three prominent groups, i.e. 
sphingolipids, gangliosides and phospholipids (Figure 6). 
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 SPHINGOLIPIDS 
sulfatide 
 
sphingomyelin 
 
iGb3 
 
GD3 
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 GANGLIOSIDES 
GM1 
 
Fucosyl-GM1 
 
GalNac GD1a 
 
GD1b 
 
GQ1b 
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 PHOSPHOLIPIDS 
phosphatidylcholine 
 
phosphatidylethanolamine 
 
phosphatidylglycerol 
 
 
Figure 6: Structures of immunogenic self lipids presented by CD1 molecules. 
 
The backbone of the sphingolipids is made of the basic alcohol sphingosine, or a related 
long-chain base usually between 14 and 24 carbon atoms long. Sphingomyelin is found in all 
cell membranes, and is composed of a ceramide (sphingosine plus an amide linkage with a 
fatty acid) with additional phosphate and choline. Addition of glucose or galactose to a 
ceramide leads to glycosylceramides. The hydrophobic lipid moiety of glycosphingolipids is 
of primary importance in terms of immunogenicity [28], as the lipid tail is involved in 
binding onto CD1. The length of the acyl chains, as well as their degree of saturation and 
rigidity, also seem to play a role [28, 154-157]. The positioning of the polar part of lipid 
antigens is influenced by the lipid moiety. The polar head makes direct interactions with the 
α-helices of the CD1 molecule, thus contributing to the formation of stable CD1-lipid 
complexes. It also interacts directly with the TCR. At this stage, it must be pointed out that, 
despite the fine antigen specificity of the TCR, lipid-specific T cells also show a certain 
degree of cross-reactivity between different lipid antigens. 
Immunogenic lipids are synthesized by enzymes at different places in the cell. For example, 
the enzymes responsible for ceramide synthesis are on the cytosolic membrane leaflet of the 
ER [158]. LTPs are implicated in the transfer of lipids between intracellular compartments. In 
the case of ceramide, CERT allows its transport to the trans-Golgi cisternae [159]. But 
ceramide can also be translocated inside the luminal membrane of the ER where it is used to 
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generate galactosylceramide [160]. Ceramide is the common precursor of sphingomyelin and 
glycosphingolipids. Sphingomyelin is mainly synthesized in the luminal part of Golgi 
apparatus vesicles [161], then traffics to the plasma membrane following the secretory 
pathway. Glycosphingolipids synthesis also occurs in the Golgi. Glucosylceramide is 
synthesized on the cytosolic leaflet of the Golgi apparatus [162]. Glucosylceramide is then 
either transported to the plasma membrane by a non-Golgi pathway and degraded [163], or 
translocated in the luminal leaflet of Golgi vesicles for further addition of sugars. Addition of 
a galactose to a glucosylceramide gives a lactosylceramide, that is the common precursor of 
other glycosphingolipids. GM3 and GD3 are synthesized in early Golgi compartments, 
whereas complex gangliosides are predominantly synthesized in the trans Golgi [164, 165]. 
Glycosphingolipids and sphingomyelin reach then the noncytosolic leaflet of membranes 
following the secretory pathway. Phospholipids, at last, are synthesized on the cytosolic 
leaflet of the ER, then move to the luminal one, where they can assemble with nascent CD1d 
[43, 45] and CD1b [133] molecules. 
Regulation of antigenic self lipid synthesis is influenced by intrinsic properties of 
glycosyltransferases, such as enzymatic kinetics and localization, but also by the relative 
abundance and activity of such enzymes [166, 167]. On the other side, physicochemical 
characteristics, trafficking capacity and availability of the sugar substrates are also factors of 
primary importance for further synthesis. Accumulation of glycosphingolipids also might 
influence the regulation of glycosyltransferases at the gene level. 
As described above, immunogenic self lipids are synthesized in the ER and Golgi. The lipids 
synthesized in the ER are transferred to other organelles by LTPs [168], that bind and 
transport lipids across aqueous phases. Specific transfer between donor and acceptor 
membranes is due to the presence of unique LTP protein domains. Again, biophysical 
characteristics inherent to each lipid can lead to preferential pathways when they are part of a 
vesicle. It may be the case for glycolipids with similar structures but differing in the length of 
their lipid tail, the ones with shorter tails recycling preferentially to early endosomes while 
the ones with long chains recycle to late endosomes [25]. The late endosomal compartment 
allows an additional sorting step into multivesicular bodies (MVB), that might help lipid 
loading onto CD1 molecules, as might do the presence of LTPs such as saposins (SAPs) and 
GM2-activator protein (GM2A) [30]. 
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During assembly in the ER, nascent CD1d associates with PC [45], maybe also with spacer 
molecules [43], as do CD1b [133]. These spacers stabilize CD1d and CD1b during their 
traffic to the cell membrane. Recycling in low-pH endosomal compartments facilitate loading 
of other lipid antigens. Indeed, changes in the proton concentration influence the charged 
state of residues in flexibles areas in the superior and lateral walls of the A’ pocket of CD1b, 
thus regulating the conformation of the CD1 groove and controlling the size and rate of 
antigens captured [169]. A subpopulation of CD1d also forms complexes with the invariant 
chain (Ii) and class II molecules [129, 170]. CD1a, that lacks tyrosine containing cytoplasmic 
tail motifs, only recycles in early endosomes. Phospholipids recycling in early endosomes are 
then efficiently presented by CD1a [155]. On the contrary, complex glycolipids traffic to late 
endosomes where they are loaded onto resident CD1 molecules, namely CD1b, CD1c, and 
CD1d. Sulphatide, a major component of myelin, can be presented by CD1a, CD1b and 
CD1c molecules [171]. 
High numbers of T cells recognizing self lipid antigens are present in the blood of patients 
suffering from MS [153]. Myelin lipids seems to be highly immunogenic [172-174], and it is 
likely that the specific T and B cell responses are correlated with the progression of MS. It 
should also be noticed that bacterial infection promotes de novo synthesis and recognition of 
self lipid antigens [175]. 
 
  Microbial Lipid Antigens 
 
 The first microbial lipid antigen described was mycolic acid [176]. Many others have 
now been identified, presented by CD1a [177], CD1b [178-180], CD1c [181], and CD1d 
[182-187] (Figure 7). 
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Figure 7: Non exhaustive structures of immunogenic microbial lipids presented by CD1 
molecules. 
 
Didehydroxymycobactins (DDMs) are lipopeptides composed of a complex peptidic 
headgroup linked to a single alkyl chain of approximately 20 carbons. They may be direct 
metabolic precursors of mycobactins, that are mycobacterial lipopeptides with iron-
scavenging properties [177]. These siderophores, presented by CD1a molecules, are of 
primary interest as they might be important for mycobacterial growth and virulence according 
to the complex enzymatic machinery devoted to their synthesis. Thus, DDMs may represent 
an early warning system highlighting intracellular pathogen infection. Again, length and 
saturation of the alkyl chain, as well as the headgroup, play critical roles in recognition by T 
cells [48, 177]. 
CD1b-restricted foreign lipid antigens all derive from the mycobacterial cell envelope and 
have no close structural homologues in mammalian cells. They include lipoarabinomannan 
(LAM), lipomannan (LM), phosphatidylinositol mannosides (PIMs) [34, 180, 188], glucose 
monomycolate (GlcMM) [179], and sulfoglycolipids (SGLs) [178]. 
Mycolic acids are a family of characteristic α-branched, β-hydroxy fatty acids produced by 
M. tuberculosis and other species of actinomyces. They constitute about 40% of the cell wall 
skeleton of mycobacteria, corynebacteria and Nocardia [189]. Mycolic acids present in the 
mycobacterial cell wall can be separated into three classes (α, methoxy, keto) and are 
between 70 and 90 carbons large, up to 26 carbons long, with meromycolate chains about 60 
carbons plus additional functional groups (methyl branches, cyclopropane rings, or double 
bonds). They might increase rigidity and lower permeability of the cell wall. Compounds that 
Mannosyl‐β1‐phosphomycoketide 
 40 
inhibit their synthesis, such as isoniazid and ethionamide, are used as antituberculosis drugs, 
confirming their importance for M. tuberculosis survival [189]. It seems that naturally 
occurring variations in the lipid tail structure are not critical for recognition of GlcMM by 
LND5, a CD1b-restricted αβ T cell clone [179]. Whether this can be considered a general 
rule is still an open question, especially because DN1, another CD1b-restricted αβ T cell 
clone, is sensitive to structural differences in the meromycolate chain [49]. However, in both 
cases, the glucose headgroup seemed of primary importance for GlcMM recognition [49, 
179]. It should also be noticed that mycobacteria are unable to synthesize GlcMM de novo, 
and need to acquire exogenous glucose from host’s infected tissues, indicating that GlcMM 
generation may be restricted to pathogenic mycobacteria capable of infection [190]. 
Mycobacterial glycosylphosphatidylinositols are CD1b-restricted lipid antigens with a 
phosphatidyl inositol core [180]. One subset, named PIMs, contain varying numbers of 
mannose residues, are restricted to actinomycetes [189] and are major components of the 
outer leaflet of the mycobacterial plasma membrane. LM and LAM are multiglycosylated 
extensions of the PIMs. LAM is heterogenous in structure, with variations between different 
mycobacterial species in terms of whether and how distal arabinose moieties possess a 
terminal mannose unit. LAM exerts a wide range of biological activities, including diverse 
effects on phagocyte chemotaxis and function, DC function and T cell migration and 
activation [191]. LAM and PIMs also induce group 1 CD1 proteins expression in human 
myeloid cells via toll-like receptor (TLR)2 [70]. TLRs are instructive pattern recognition 
receptors (PRRs) providing APCs with signals that regulate their capacity to elicit T cell 
responses [192]. Both hydrophilic and carbohydrate structures are important for recognition 
of LM, LAM and PIMs [180]. 
SGLs have recently been identified as CD1b-restricted antigens recognized by M. 
tuberculosis-specific T cells [178]. They are mycobacterial cell envelope molecules that 
possess a trehalose 2’ sulfate core acylated by two to four fatty acids. These fatty acids can be 
palmitic (C16), stearic (C18), hydroxyphtioceranoic (C32), or phtioceranoic (C32). They also 
seem to exert many biological activities, including anti-tumor activity [193]. The extent of 
their expression in M. tuberculosis correlates with strain virulence in guinea pigs models 
[194]. The active antigenic species have been shown to be diacylated sulfoglycolipids 
(Ac2SGLs) containing hydroxyhtioceranoic and either palmitic or stearic acid chains. 
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Presentation of Ac2SGLs is efficient during infection, and induces production of IFNγ by 
specific human T cells and subsequent killing of intracellular bacteria in vitro [178]. 
The first CD1c-restricted antigens to be defined structurally were isolated from lipids in the 
cell wall of both M. avium and M. tuberculosis [181], and shown to be closely related to 
mannosyl β-1-phosphomycoketides (MPMs). They are also referred to as mannosyl 
phosphoisoprenoids (MPIs), because of their structure containing a single fully saturated 
alkyl chain similar to isoprenoid lipids, with methyl branches at every four carbons. Their 
structure is close to mammalian mannosyl phosphodolichols (MPDs), with an identical 
mannosyl β-1 headgroup, but with lipid tails that are saturated and much shorter in the case 
of mycobacterial MPMs. The stimulatory MPM antigens are only present in cell wall extracts 
from mycobacteria and are restricted to species that can infect human cells [195]. Also in the 
case of MPMs, both headgroup and alkyl chain are of primary importance for recognition by 
T cells [181, 195, 196]. All CD1a-, b- and c restricted foreign antigens defined to date derive 
from mycobacteria, suggesting a role for group 1 CD1-restricted responses in immunity to 
these pathogens. These CD1 molecules are expressed at the site of mycobacterial infection, 
and their expression correlates with effective host immune response in leprosy patients [71, 
197, 198]. It seems that group 1 CD1-restricted T cells preferentially secrete Th1 cytokines 
[199, 200], thus contributing to protective immunity to mycobacteria and rendering antigens 
presented by these molecules good candidates for vaccine formulations. 
It should be noticed that CD1d binds α-galactosylceramide (α-GalCer), a foreign 
glycosphingolipid from marine sponges resembling mammalian ceramides [201]. α-GalCer is 
composed of a sphingosine base, an amide-like acyl chain, and an O-linked galactose sugar 
with an α-linkage, whereas mammalian ceramides possess a β-linkage. It is still unclear 
whether α-GalCer has to be considered as an antigen or an agonist, since it has not been 
found elsewhere than in sponges. However, mice treated with α-GalCer have increased 
resistance to infection by viruses, mycobacteria and trypanosomes. GPI structures linked to 
proteins derived from protozoan pathogens were the first lipids proposed to function as 
exogenous antigens for iNKT cells [202]. PIM4 [183], as well as other phosphatidylinositol 
(PI)-related lipids derived from protozoan parasites [182], have also been proposed as foreign 
antigens restricted by CD1d. These three types of putative antigens are still a matter of 
debate. Recent data show that bacterial glycosphingolipids with α-anomeric linkages, such as 
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α-glucuronosyl-ceramide (GSL-1) and α-galacturonosyl-ceramide (GSL-1’), as well as 
sulfatide variants, are presented by CD1d and are capable to activate iNKT cells [184-187]. 
Recently, threitolceramide has also been shown to behave as an agonist, but it is unclear 
whether such nonglycosidic compounds are naturally synthesized [203]. Group 2 CD1-
restricted T cells have been implicated in broad antimicrobial responses to bacterial, parasite, 
viral and fungal infections [204]. They are currently considered as linking innate and 
adaptative immunity. 
 
 Lipid Antigen Presentation 
 
  Lipid uptake by APCs and intracellular trafficking 
 
 Phase fluid antigens are extensively taken up by APCs via macropinocytosis. In the 
case of exogenous lipids, many other mechanisms might play a significant role (Figure 8). 
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Figure 8: Internalisation and loading of lipid antigens onto CD1 molecules. In the ER, 
nascent CD1 are stabilized by resident lipids, and MTP is thought to facilitate this process. 
Exogenous lipid antigens enter the cell by phagocytosis or interaction with LDL receptors, C-
type lectins, or scavenger receptors. Then, exogenous lipids traffic to late 
endosomal/lysosomal compartments through clathrin-coated pit vesicles. Plasma membrane-
resident lipids are internalized through clathrin-coated vesicles as well, but also through 
caveolae, and their distribution to sorting endosomes is probably controlled by their intrinsic 
physico-chemical properties. In the lysosomes, complex glycolipids are processed by 
enzymes, with the participation of LTPs and CD1e. 
 
The majority of circulating lipids are transported as soluble complexes bound to lipoproteins 
[205]. These lipoproteins organize lipids into particles of variable density called very-low-
density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL). The core of these particles is largely composed of triglycerides and cholesteryl esters, 
sphingolipids, and fat-soluble vitamins. Apolipoprotein E (ApoE) has recently been proposed 
as a carrier, present in the serum, that binds exogenous lipid antigens and increases their 
uptake by DCs via lipoprotein receptors, as well as their subsequent presentation by CD1 
molecules [29]. Scavenger receptors, like CD36 and SR-B1, as well as LDL-R-like protein 
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(LRP), may also participate in lipid uptake through binding of ApoE or lipidic ligands [206-
208]. Even if LRP and scavenger receptors have not yet been implicated in CD1-based 
antigen uptake, they look like attractive candidates. Thus, lipoprotein receptors and scavenger 
receptors are cell surface receptors that have the capacity to bind lipid particles. 
Other cell-surface receptors bind glycans instead of particles. It is the case of C-type lectins, 
like the macrophage mannose receptor (MMR) or langerin, that allow distribution of lipids 
into the endocytic compartments, hence participating in CD1 antigen presentation [27, 209, 
210]. 
The uptake of lipids into the endocytic system may also occur based on their incorporation 
into the plasma membrane that is then taken up as part of general endocytic processes [211], 
thus being receptor-independent. Phagocytosis, macropinocytosis, micropinocytosis that is 
clathrin-mediated or -independent, all result in the uptake of the plasma membrane that may 
have incorporated lipid antigens. The so-called rafts (cholesterol- and sphingolipid-rich 
plasma membrane microdomains) may differentially incorporate lipid antigens based on their 
resident lipid composition [212]. Both rafts and caveolae (caveolin-containing subdomains of 
glycolipid rafts) are internalized [213], and might deliver lipid antigens to CD1-loading 
endosomal compartments. CD1a is enriched in detergent-resistant membrane microdomains 
that are essential for efficient CD1a-mediated antigen presentation [145]. Disruption of these 
lipid rafts inhibits CD1a-restricted presentation [146]. ABC transporters are pumps also 
involved in lipid trafficking across the bilayer [214], and fatty acid transport proteins 
(FATPs) have been found to mediate uptake of long chain fatty acids as well [215, 216]. 
Finally, uptake of apoptotic bodies from cells infected with microbes by APCs may also lead 
to lipid antigen presentation via the CD1 molecules of the APCs [217]. 
Cellular membranes show regulated changes in their density within a single membrane, and 
individual organelles differ in their membrane lipid composition. Because lipids do not 
display recognized targeting motifs, it is thought that their distribution is controlled by their 
chemical and physical properties [218, 219]. Glycerophospholipids and sphingolipids are 
major constituents of cellular membranes, and many of the CD1 ligands fall into one of these 
two lipid groups, raising the possibility that membrane microdomains may potentially 
contribute to sorting lipid antigens [213]. It has also been shown that lipid analogs that differ 
only in the length and saturation of their tails are sorted distinctly [220]. Similarly, it seems 
that GlcMM with long alkyl chains is preferentially sorted to late endosomal compartments, 
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whereas it is not the case for GlcMM with shorter ones [25]. Early recycling compartments 
are rich in cholesterol and sphingolipids, whereas late endosomal/lysosomal ones are 
enriched in neutral lipids such as triglycerides and cholesterol esters [218]. It seems that the 
differential trafficking of both lipids and CD1 molecules enables a broad intracellular survey 
of the cell. In the context of mycobacterial infection, antigen delivery in the right 
compartment is a critical point, as prevention of lysosomal delivery is a strategy developed 
by pathogens to escape innate immunity [221, 222]. For information, a leukocyte-specific 
protein named coronin 1 has recently been shown to act as a primary player in phagosomal-
lysosomal fusion blockade, ensuring survival of mycobacteria inside macrophages [223]. 
 
  Antigen processing and loading onto CD1 
 
 Lipid loading onto CD1 molecules can take place in both extra- and intracellular 
compartments, from the cell surface to the lysosomes, including the ER and early recycling 
compartments (Figure 8). Loading of αGalCer onto CD1d happens either on the plasma 
membrane or in lysosomes [224]. Late endosomes/lysosomes provide an ideal environment 
for antigen processing and loading, i.e. processing enzymes and acidic conditions. For 
example, mycobacterial PIM6 is processed to PIM2 by lysosomal α-mannosidase with the 
help of CD1e [34]. LTPs have recently been proposed for lipid extraction from membrane 
bilayers and transfer onto CD1 molecules. It is the case for SAPs and GM2A [30, 225, 226]. 
SAPs A, B, C and D are enzymatically inactive glycoproteins generated by endosomal 
proteolytic cleavage of the precursor prosaposin, while GM2A is encoded on a separate gene. 
SAPs localize to late endosomes/lysosomes and assist glycosphingolipid degradation [227]. 
The SAPs share lipid-binding and membrane-perturbing properties, but differ in their binding 
specificity and mode of action. SAP C interacts directly with, and activates, the enzyme 
glucosylceramide-β-glucosidase for glucosylceramide degradation [228-230]. SAP B 
interacts with a variety of sphingolipids and facilitates their digestion by specific lysosomal 
enzymes [231-236]. All the four saposins are capable of transferring phosphatidylserine (PS); 
and SAP A, B and C transfer sulfatide to CD1d [30]. In addition, SAP-dependent antigen 
processing and loading pathways have also been noted for human CD1b-presented glycolipid 
antigens of microbial origin [226]. GM2A associates with β-hexosaminidase A and assists 
GM2 degradation. GM2A can bind GM2, but also GT1b bound to CD1d and remove it from 
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the CD1d antigen-binding groove [30]. However, it has recently been shown that lysosomal 
accumulation of lipids impairs lipid antigen presentation, and therefore should be considered 
in the interpretation of immunological deficiencies observed in the presence of lipid 
metabolic disorders [237]. 
 
  Persistence of CD1-lipid antigen complexes 
 
 Prolonged exposition of CD1-lipid antigen complexes on the surface of APCs 
facilitates interaction with specific T cells, thus affecting their immunogenicity. CD1b and 
CD1c molecules form immunogenic complexes with half-life shorter than 24 h, whereas 
CD1a persists at least three days, as measured on living DCs [171]. CD1d complexes with 
different glycosphingolipids have a half-life longer than 24 h [43, 238, 239]. This difference 
might be ascribed to the intracellular compartment wherein CD1 molecules traffic, with a 
faster degradation of the immunogenic complexes in LE/lysosomes. 
 
 Lipid-reactive TCRs and selection of CD1-restricted T cells 
 
 Lipids are recognized by T lymphocytes that express αβ TCRs and are called 
“unconventional” T cells because they might have different properties than “conventional” T 
cells that recognize peptides presented by MHC class I and class II proteins. The group of 
unconventional T cells also includes MHC class I-reactive T cells that co-express NK cell 
receptors such as NK1.1, and T cells reactive with nonclassical class I or class Ib molecules. 
T cells reactive with CD1d can express a semi-invariant TCR (Vα24-Jα18 and variable Vβ11 
chains in humans, Vα14-Jα18 and Vβ8.2, Vβ7 or Vβ2 chains in mice) [240-243], or not 
[244, 245]. The T cells reactive with human CD1a, CD1b, and CD1c molecules have diverse 
TCRs [204, 246]. In general, T cells reactive to a particular CD1 molecule can express either 
CD4, CD8, or are double negative [247]. The large percentage of double negative CD1 
reactive T cells suggests that the TCRs of glycolipid reactive T cells may be co-receptor 
independent. This would be of primary importance as the co-receptors enhance both TCR 
avidity [248] and transduction of the signal [249]. 
iNKT cells, that are CD1d-restricted, are naturally occurring memory-like populations with 
the capacity to produce both pro- and anti-inflammatory cytokines rapidly after TCR 
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engagement. iNKT cells have the capacity to alter the initiation of an adaptive immune 
response by augmenting or dampening the early immune response, or by diverting it in either 
a T helper type 1 or T helper type 2 direction. In the thymus, T cell precursors recombine 
genes of their TCR β and α loci and test the paired chains against the pool of self-MHC-
antigen complexes expressed predominantly by epithelial cells for positive selection and 
dendritic cells, among others, for negative selection. T cell precursors with intermediate-
affinity αβ TCRs mature, while those with high- and low-affinity are deleted. After random 
TCR rearrangements, iNKT cells are positively selected by other double positive cortical 
thymocytes that probably express CD1d in association with endogenous glycolipids [250, 
251], and the positive selection signal is thought to be agonistic [252]. How or whether 
negative selection occurs remains controversial. Then, iNKT cells undergo differentiation and 
maturation [253-256]. Even if the thymic development of iNKT cells shares features with the 
development of conventional CD4+ and CD8+ T cells, iNKT cells differentiation requires 
genes involved in the presentation or recognition of the selecting antigen such as CD1d, TCR 
Jα18, prosaposin, hexosaminidase B, ap3, and cathepsin L [257, 258]. Some signaling 
molecules and transcription factors are required as well for iNKT cells differentiation. They 
include fyn, SLAM-associated-protein, DOCK2, T-bet, IL-15 and members of the ets and 
NF-κB families [149, 257-260]. iNKT cells are usually identified by staining using tetramers 
composed of CD1d and αGalCer or αGalCer analogs. Interestingly, and contrary to peptide-
MHC complexes [261], iNKT TCR binding to αGalCer-CD1d complexes was not found to 
be temperature-dependent [238, 262], suggesting low versatility in CD1d-lipid-TCR binding. 
It also seems that the avidity interactions between CD1d-lipid complexes and the TCR of 
iNKT cells are stronger than the ones observed for peptide reactive T cells [44, 239, 248, 
262-264]. Affinities and half-life of CD1d-lipid complexes with iNKT TCR vary according 
to the structure of the lipidic compound [238, 262, 263], but CD1d complexes with different 
glycosphingolipids have a relatively long half-life, i.e. more than 24 h [43, 238, 239]. Crystal 
structures of several human TCRs that bind αGalCer have been solved [265, 266], and 
recently also the mouse TCR that recognizes the complex mCD1d-iGb3 [47]. Each TCR has 
an architecture similar to conventional TCRs, with two immunoglobulin (Ig)-like V domain 
(Vα and Vβ) and two constant (Cα and Cβ) domains. The glycolipid-CD1d-specific binding 
surface of the TCR contains a pocket formed by complementarity-determining regions 
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CDR1α, CDR3α, CDR1β and CDR3β, and seems to be flexible due to conformational 
changes of the CDR3 loops [47, 266]. It should be noticed that, even if nearly all iNKT cells 
are αGalCer-reactive [241], some heterogeneity in lipid-reactivity exists, probably reflecting 
the diversity of the β chain. Thus, some iNKT cells react to GD3 [267] and phospholipids 
such as PI and phosphatidylethanolamine (PE) [154, 268, 269]. 
CD1d-dependent NKT cells that do not express the invariant Vα14-Jα18 rearrangement also 
exist [244, 245, 270, 271], and they are called type II NKT cells [272]. Type II NKT cells are 
not dependent on the ability of CD1d to traffic to endosomes for their autoreactivity [273], 
contrary to iNKT cells for which CD1d trafficking to endosomes is required for selection 
[143] and autoreactivity [273]. iNKT and type II NKT cells seem to be functionally distinct 
[274, 275], and iNKT are less abundant than type II in human bone marrow [276]. Type II 
NKT cells are likely to recognize diverse antigens [244], including sulfatide [175] and 
nonlipidic sulfonate-containing small molecules [277]. 
Mucosal invariant T cells (MAIT) are a second population of invariant NKT cells found in 
mice and humans. They express an invariant Vα19-Jα33 TCR in mice and Vα7.2-Jα33 
rearrangement in humans. They are reactive to MR1, a non-polymorphic MHC class I-like 
antigen-presenting molecule. CD1d and MR1 are encoded in the same region of chromosome 
1 in a locus paralogous to the MHC [278]. The majority of mouse Vα19i MAIT cells are 
NK1.1+ and double negative, they express a restricted set of Vβ regions, are selected by 
hematopoietic cells in the thymus, and rapidly produce effector cytokines such as IL-4 after 
TCR activation [279, 280]. However, Vα19i MAIT cells are functionally different from 
iNKT cells, as Vα19i MAIT cells are uniquely dependent upon B lymphocytes and the gut 
flora for their normal accumulation in the periphery, and are enriched in the intestinal lamina 
propria [279, 280]. It has also been suggested that Vα19i MAIT cells are reactive to 
mannose-containing glycolipids presented by MR1 [281, 282]. 
The T cells reactive with group 1 CD1 molecules recognize a variety of antigens including 
mycolic acids, phospholipids, glycosphingolipids, polyisoprenols glycolipids, diacylated 
sulfoglycolipids, and lipopeptides [204]. Group 1 CD1-reactive T cells are a diverse set of 
lymphocytes that can express either CD4, CD8, or are double negative. They can react to self, 
foreign, or both type of antigens [283]. αβ T cells restricted to CD1a, CD1b, or CD1c are 
highly diverse, with junctional diversity in both the α and β chains and N nucleotide 
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additions [246, 283]. The αβ  TCR is the most frequently expressed, but also γδ T cells 
expressing Vδ1 are reactive to CD1a [155] and CD1c [284]. 
 
 CD1-restricted T cells implication in disease 
 
 CD1 molecules have the potential to function as key components of a microbial 
recognition system that alerts the immune system to the presence of pathogens harboring 
relevant lipid targets as part of their essential structure. However, the importance of this 
system in adaptive and innate immune responses is not completely evaluated yet. The 
function of the group 1 CD1 isoforms seems closely linked to adaptive immunity, while 
group 2 CD1 molecules have been predominantly associated with innate immunity. 
One major limitation to the study in vivo of CD1-restricted T cell responses is the absence of 
group 1 CD1 molecules and CD1e in mice. Nevertheless, they express CD1d, making them 
valuable models for the study of group 2 CD1-restricted T cells. 
The effect of infection on group 1 CD1 proteins expression is unclear. Positive or negative 
modulation depends on several factors including the pathogen involved, the differentiation 
state of the APC at the time of infection, or even the local microenvironment [70, 71, 285-
291]. Group 1 CD1-restricted T cells specific for M. tuberculosis are generally detectable 
only in humans with positive tuberculin skin tests, which are indicative of previous infection 
with M. tuberculosis [152, 178, 181], corresponding to sustained memory responses 
characteristic of adaptive immunity. Animal models expressing group 1 CD1 molecules, 
including guinea pigs, rabbits, cows, and nonhuman primates, may be useful for further 
studies. Infection and vaccination studies in guinea pigs have already provided significant 
results, including protection against virulent M. tuberculosis organisms [292, 293], 
highlighting the fact that group 1 CD1-restricted T cell responses can be potentially exploited 
for development of novel vaccination strategies against M. tuberculosis and possibly other 
organisms that contain relevant lipid antigens. 
Group 2 CD1-restricted T cells are also thought to contribute to immunity against infection. 
Indeed, αGalCer treatment has been shown to improve the outcome of infection, indicating 
that iNKT cells have the potential to enhance immunity against microbial pathogens [294-
296]. Several microbial lipids that bind CD1d have been identified, but it is still uncertain 
whether CD1d-restricted T cells that recognize these antigens are elicited during infection 
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[154, 182-185, 297, 298]. During infection, cytokines and TLR signals increase CD1d levels 
on APCs, which promote NKT cell activation [119, 121, 299]. TLR ligands expressed by 
microbial pathogens can also induce cells such as macrophages or DCs to produce soluble 
mediators that co-stimulate NKT cell activation [185, 300], thus validating a model in which 
pathogen-induced TLR-dependent IL-12 production co-stimulates a weak TCR signal 
generated by the recognition of self antigens presented by CD1d and leads to NKT cell 
activation during infection. CD1d-restricted T cells can act as direct effector cells via 
cytolysis or granulysin [301], and their IFNγ production can activate macrophages to become 
more microbicidal. In addition, iNKT cells can rapidly generate large amounts of IL-4 and 
IFNγ, that can modulate the function of other cells, by activating NK cells [302, 303], 
inducing MHC on macrophages and DCs, and modulating the T helper (Th)1/Th2 balance of 
CD4+ T cell responses [156, 157, 239, 304-307]. In the case of Streptococcus pneumoniae or 
Pseudomonas aeruginosa infections, the number of iNKT cells in the lung increase, and they 
produce cytokines such as tumor necrosis factor (TNF) and macrophage inflammatory 
protein-2, which lead to the accumulation of neutrophils in the lung and subsequent 
phagocytosis of the pathogens [308, 309]. CD1d-restricted NKT cells are also thought to 
have an early impact on immunity to Borrelia burgdorferi, the causative agent of Lyme 
disease, by regulating inflammatory reactions [310]. They are also implicated in regulation of 
inflammation subsequent to infection with parasites [311-317]. Viral infection can modulate 
CD1d expression [318] or trafficking [122]. For example, HIV-1 downregulates CD1d 
expression by increasing its internalization from the cell surface [120], whereas hepatitis C 
virus increases CD1d levels on hepatocytes and infiltrating mononuclear cells of patients 
with the chronic form of the disease [99, 319]. Studies on mouse models of autoimmune 
diseases, including Experimental Autoimmune Encephalomyelitis, Diabetes, Arthritis, and 
Lupus, clearly pointed out a critical role for iNKT cells in regulation of autoimmunity. Even 
if results are still controversial regarding the mode of action, it seems that protection is rather 
mediated by Th2 cytokines produced by iNKT cells than Th1 ones [156, 157, 320-335]. Also 
for dextran sodium sulfate-induced colitis, an experimental model of Crohn’s disease, 
activation of iNKT cells seems to have a protective effect [336]. In humans, the number of 
iNKT cells in the peripheral blood of patients is reduced in systemic sclerosis [337], multiple 
sclerosis [338-340], and other autoimmune diseases [341-343]. Their putative role in type 1 
diabetes is still a matter of debate [344-347]. iNKT cells also appear to play a critical role in 
 51 
allergic inflammatory responses, particularly in the development and pathogenesis of asthma 
and airway hyperreactivity (AHR) [348-351]. The fact that iNKT cells are relatively resistant 
to corticosteroid treatment renders them a target of choice for the establishment of new 
medications [352-355]. Subsets of iNKT cells with restricted cytokine profiles have already 
been described: human CD4+ iNKT cells produce both Th1 and Th2 cytokines, whereas CD4-
CD8- or CD8+ produce only Th1 cytokines and exhibit greater cytotoxic activity [356, 357]. 
CD4+ iNKT cells with a Th2-restricted profile also exist [348]. iNKT cells are also involved 
in allergic diseases other than Asthma, including Contact Sensitivity, a skin reaction 
mediated by conventional CD4+ T cells, dependent upon the presence of IL-4+ iNKT cells 
[358] and CD1d glycolipid presentation [359]. Some studies also indicate an imbalance in 
CD4+ iNKT cells in atopic dermatitis, but little is known about their precise involvement 
[360-362]. 
To date, only CD1d-restricted T cells have been implicated in tumor immunity, maybe 
reflecting the fact their study is more easily addressed experimentally as CD1d is the only 
member of the CD1 family present in the mouse genome. Mice lacking iNKT cells are more 
susceptible to tumor growth, with both an earlier onset of tumor development and higher 
tumor incidence [363], suggesting that iNKT cells play a role in mediating anti-tumor 
immunity. Antigenic lipids may either come directly from the tumor, and/or could also 
correspond to altered endogenous ones. For example, the ganglioside GD3 is a tumor-
released glycolipid antigen that is cross-presented to iNKT cells by APCs rather than directly 
by the tumor cells themselves [267]. αGalCer was isolated during a screen for anti-cancer 
agents [364, 365], possess a potent anti-tumor activity [366-369], and iNKT cells are required 
for its effectiveness [368, 370]. Patients with malignant melanoma or prostate cancer have 
decreased numbers of circulating iNKT cells [371, 372]. iNKT cells functions in leukemia 
have also been studied, and they are able to efficiently kill the tumor cells [101, 102, 104]. In 
patients with progressive multiple myeloma, iNKT cells have an impaired ability to secrete 
IFNγ [373]. Intra-tumor iNKT cell frequency has recently been identified as a prognostic 
factor in primary colorectal carcinomas, the prognosis being improved for patients exhibiting 
high iNKT cell infiltration [374]. In another study, it has also been shown that the number of 
iNKT cells is diminished in the liver of colon cancer patients with hepatic metastasis [375]. It 
seems that also noninvariant CD1d-restricted NKT cells are able to regulate tumor immunity 
[376-379] and autoimmunity [380], thus broadening even more the impact of CD1-related 
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immune responses. In humans, noninvariant CD1d-restricted NKT cells have been identified 
in the bone marrow [276], and among the intrahepatic lymphocytes of patients with hepatitis 
C [381]. 
 
 Therapeutic applications of Lipid Antigens 
 
 Current vaccination strategies using recombinant viruses are facing limitations due to 
high responses against the viral proteins, which out-number responses specific for 
recombinant protein antigens [382, 383]. Advances in molecular technology have permitted 
the design of synthetic protein vaccines, providing immunotherapy with a degree of 
specificity that has not been possible using traditional vaccines based on live attenuated 
pathogens or whole inactivated organisms. Such specificity is providing a platform for the 
design of T cell therapies for infectious diseases and cancer. Optimisation of such vaccination 
strategies requires a deeper understanding of the signals that the immune system coordinates 
to respond to pathogenic infections. Compounds that mimic these signals, such as those 
capable of activating CD1-restricted T cells, should therefore be exploited in current 
vaccination protocols. That is the reason why microbial lipids, which are the products of 
multistep enzymatic synthesis and are often significantly different from mammalian lipids, 
appear to be perfect targets for vaccine development. Furthermore, the minimal 
polymorphisms present in the CD1 genes suggest that vaccination with microbial lipids has 
the potential to stimulate protective immunity in ethnically diverse populations. 
As described above, CD1d-restricted NKT cells rapidly release large amounts of both Th1 
and Th2 cytokines, and are able of both enhancing and suppressing immune responses [304]. 
The existence of functionally distincts subsets of CD1d-restricted T cells [357, 384, 385] may 
explain the different outcomes following their activation. Fine-tuning their activation in vivo 
might be of primary importance for therapeutic purposes. 
αGalCer has been tested in phase I clinical trials involving patients with solid tumors, 
metastatic malignancies and non-small cell lung carcinoma [386-389]. These tests 
demonstrate that αGalCer can be safely used to activate iNKT cells in human cancer patients, 
although they displayed various efficacy. Other strategies involve modification of αGalCer 
itself to bias the iNKT cell-mediated response towards secretion of Th1 or Th2 cytokine 
profiles [156, 306], polarization of iNKT cells in vitro before transfer into patients [390], or 
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addition of cytokines during therapy to enhance efficacy of αGalCer [391, 392]. Addition of 
αGalCer to tumor vaccination schedules has also proven to be an effective way of boosting 
antigen-specific CD4+ and CD8+ T cell responses in mice [393-395], a phenomenon mainly 
dependent on the ability of iNKT cells to stimulate DC maturation and cross-presentation. In 
this case, both glycolipid and peptide antigen must be presented by the same APCs for 
effective enhancement of T cell responses [395]. Injections of αGalCer or OCH, a 
sphingosine-truncated analog of αGalCer, confer protection against type I diabetes and 
experimental autoimmune encephalomyelitis (EAE) via Th2 responses [156, 396, 397]. 
However, treatment with soluble αGalCer can also induce long-term anergy in the iNKT cell 
subset [398-400]. 
It has been shown that cytokines have the ability to induce iNKT cell tumor immunity. 
Administration of IL-12 at low doses prevents the growth of tumors in an iNKT and NK cell-
dependent fashion [401-406]. IL-18 combination with IL-12 induce iNKT cell-dependent 
tumor rejection and enhances NK cell function [407]. In addition, GM-CSF-secreting 
irradiated whole cell tumor vaccines have shown good efficacy in mouse models [408]. They 
seem to require the presence of iNKT cells [409], and have some potential in clinical settings 
[410]. Recently, therapy with a pegylated form of granulocyte-colony stimulating factor (G-
CSF) was shown to mediate potent anti-leukemia responses in an iNKT cell-dependent 
manner [411]. Another example is treatment with progenipoietin-1, a chimeric cytokine of G-
CSF and FMS-like tyrosine kinase 3 ligand (Flt-3L). Progenipoietin-1-mediated expansion of 
donor CD1d-restricted NKT cells has been proved important to reduce Graft-versus-host 
disease (GVHD) in a model of allogeneic stem cell transplantation [411]. 
Apparently, effective activation of CD1d-restricted T cells in vivo is dependent on the route 
of administration of the activating ligand. Intravenous and intraperitoneal injection of DCs 
loaded with αGalCer leads to CD1d-restricted T cell activation and subsequent cytokine 
production [395, 400], whereas subcutaneous administration seems less effective [394], 
possibly due to the low frequency of CD1d-restricted T cells in the region of injection [398]. 
The adjuvant effect of CD1d-dependent NKT cell stimulation was also observed after nasal 
[412] or oral administration of protein vaccine and αGalCer [413, 414]. 
It also seems that iNKT cell-mediated anti-tumor responses can be augmented by chemokines 
[415], as chemokines enhances the migration and subsequent activation of effector cells. 
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Overall, the results of initial clinical trials are encouraging. Future trials should be based on 
the use of stimulatory CD1-restricted T cell agonists which would ensure optimal DC 
maturation without over-stimulating T cells. Identification of compounds with the ability to 
modulate the lymphokine profile appears of primary importance. Design of agonists with 
variable TCR binding affinity and variable CD1 binding stability might allow such tuning of 
the immune response. 
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CHAPTER 1 
 
 
Mycolic acids constitute a scaffold for mycobacterial 
lipidic antigens stimulating CD1b-restricted T cells 
 
(These results have been accepted for publication in Chemistry & Biology) 
 
 Mycobacterium tuberculosis, the causative agent of tuberculosis, is a microbial 
pathogen that stimulates both conventional and unconventional T cells upon infection. As 
described before, conventional T cells utilize a TCR αβ to recognize peptide antigens 
presented by MHC class I or MHC class II molecules on the surface of APCs. 
Unconventional T cells comprise TCR γδ cells specific for mycobacterial phosphorylated 
ligands, and TCR αβ cells that recognize lipid antigens presented by CD1 molecules [40, 
416, 417]. CD1 are MHC class I-like molecules and comprise five members (CD1a, b, c, d 
and e). CD1a-d directly interact with the TCR, whereas CD1e is involved in processing of 
mycobacterial PIM6 and therefore plays a role in CD1b-restricted immune response [34]. 
CD1-restricted T cells are activated during the course of M. tuberculosis infection [152, 178, 
181], and might contribute to protection during infection since they exhibit effector functions, 
including cytotoxicity and secretion of pro-inflammatory cytokines, which in turn promote 
macrophage bactericidal activity. Some lipids from the mycobacterial envelope have been 
shown to be immunogenic (Figure 9), and are considered as promising candidates to enhance 
the protective effects of subunit vaccine formulations [418, 419]. Indeed, lipid antigens 
present interesting features: first, selection-induced structural variation is unlikely as they are 
products of multi-step biosynthesis; and second, stimulatory lipids might be immunogenic in 
the entire population due to limited CD1 polmorphism. 
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Figure 9: Schematic representation of the cell envelope of M. tuberculosis. The cell wall is 
mainly composed of peptidoglycan (grey), arabinogalactan (blue), and mycolic acids (green), 
all three structures being covalently linked. The mycomembrane has low fluidity, and its 
outer part contains various free lipids, including phenolic glycolipids, SGLs and PIMs, that 
are intercalated with the mycolic acids. Most of these free lipids are specific for 
mycobacteria. The outer layer (capsule) mainly contains polysaccharides (glucan and 
arabinomannan). 
 
Vaccination of guinea pigs with M. tuberculosis lipids has already been shown to improve the 
course of the pulmonary pathology [292, 293]. Here, we tried to further characterize the 
repertoire of mycobacterial lipidic antigens in search for new candidates to be included in 
subunit vaccines. 
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 Systematic approach 
 
 In order to identify new antigenic lipids from mycobacteria, we developed a 
systematic approach consisting of extraction of lipids from mycobacteria, fractionation of 
these extracts according to polarity and charge, and generation of T cell clones with the 
fractionated material [178]. T cell activation assays allow to define the antigenic lipid species 
after additional fractionation steps. The stimulatory species is then identified using chemical 
and biochemical techniques, and the responding T cell clone is further characterized. The 
antigen-specific T cell response is then assessed in vitro using cells and samples from 
patients. 
 
 Results 
 
 Characterization of the Z5B71 T cell clone 
 
 T cell clones were generated using three types of crude mycobacterial lipidic fractions 
differing in their polarity and charge [178]. One of these clones, named Z5B71, was isolated 
after stimulation with a lipid fraction isolated from M. bovis bacillus Calmette-Guérin (BCG) 
and enriched in PIM2. Z5B71 T cells use a TCR αβ and are CD4+. They were reactive to 
lipidic extracts from all mycobacterial species tested, i.e. M. bovis BCG, M. smegmatis, M. 
gastri, M. marinum, M. fortuitum, M. xenopi, M. kansasii, M. tuberculosis H37Ra and 
H37Rv, and also to lipids isolated from Corynebacterium glutamicum and Nocardia 
asteroides (Figure 10A and 10B). This means that the immunogenic lipid is probably 
ubiquitous in bacteria belonging to the Corynebacteria-Mycobacteria-Nocardia group. 
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Figure 10: Immunogenicity of lipidic fractions from various bacterial species of the 
Corynebacteria-Mycobacteria-Nocardia group (A and B). IFNγ release was used to quantify 
T cell activation and is expressed as the mean ng/mL (± SD; n=3). The data are representative 
of three independent experiments. 
 
In all tests, the M. bovis BCG extract always appeared the most stimulatory, suggesting that 
the antigen is more abundant in this species. As M. bovis BCG glycolipid diversity is lower 
compared to that of M. tuberculosis, we decided to use M. bovis BCG lipid extracts to isolate 
and identify the stimulatory antigen. The lipid extract was first partitioned by acetone 
precipitation (Figure 11A), and the acetone insoluble fraction showed the strongest activity 
(Figure 11B). A further methanol precipitation allowed us to determine that the methanol-
insoluble fraction was the most stimulatory (Figure 11C). This latter fraction was then 
fractionated on a silica gel column and eluted with chloroform containing increasing amounts 
of methanol (Figure 11A). 
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Figure 11: (A) Purification scheme of GroMM from M. bovis BCG. (B and C) The 
purification was followed by assessing immunogenicity of the lipidic fractions. IFNγ release 
was used to quantify activation of the T cell clone Z5B71 and is expressed as the mean 
pg/mL (± SD; n=3). The data are representative of three independent experiments. 
Purification was done by collaborators. 
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Fractions 5 to 9, eluted with chloroform or chloroform/methanol 95/5 (v/v), were able to 
stimulate Z5B71 T cells (Figure 12). 
 
 
 
Figure 12: Immunogenicity of acetone insoluble/methanol insoluble lipidic fractions. IFNγ 
release was used to quantify T cell activation and is expressed as the mean ng/mL (± SD; 
n=3). The data are representative of three independent experiments. 
 
The homogeneity of the product contained in these fractions was confirmed by thin layer 
chromatography (Figure 13). 
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Figure 13: TLC analysis of eight representative fractions (fractions 1, 3, 5, 10, 18, 19, 28 and 
34) obtained after purification of acetone insoluble/methanol insoluble lipids by silica 
chromatography. The encircled spot corresponds to the active compound. TLC was done by 
collaborators. 
 
  Chemical characterization of the lipid antigen 
 
 Fractions 5 to 9 were pooled, and the product was analysed by matrix-assisted laser 
desorption/ionization-time-of-flight-mass spectrometry (MALDI-Tof-MS) and nuclear 
magnetic resonance (NMR). The positive mode MALDI mass spectrum showed a complex 
pattern of peaks assigned to cationized sodiated molecular ions [M+Na]+ (Figure 14A). The 
main peaks were characterized by 28 mass units difference, suggesting differences of two 
methylenic units between each molecular species, possibly reflecting heterogeneity in fatty 
acid length. 
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Figure 14: (A) MALDI-Tof-MS analysis in positive mode of M. bovis BCG GroMM. (B) 
Mycolic acids obtained after alkaline hydrolysis of M. bovis BCG GroMM. The asterisk 
corresponds to a contaminant. (C) Estimated masses of sodium adducts corresponding to 
expected mycolic acids and subsequent GroMM. MALDI-Tof-MS analysis was done by 
collaborators. 
 
To confirm this assumption, the product was hydrolyzed under alkaline conditions and the 
fatty acids were analysed by gas chromatography (GC) (not shown) and MALDI-Tof-MS 
(Figure 14B). The positive mode MALDI mass spectrum revealed a series of peaks typical of 
mycolic acids [420]. Mycolates are classified into α-mycolates, methoxymycolates, and 
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ketomycolates, according to the presence of various chemical functions on the meromycolic 
chain [421]. M. tuberculosis contains a ratio α-mycolates/oxygenated mycolates (i.e. 
methoxymycolates and ketomycolates) of 1/1, while M. bovis BCG contains predominantly 
ketomycolates [422]. In agreement with these data, peaks at m/z 1232, 1260, 1274, 1288 and 
1302 (Figure 14B) were assigned to [M+Na]+ forms of ketomycolates (Figure 14C). The 74 
atomic mass units difference with the native product suggested that the latter consisted of one 
mycolic acid esterifying a glycerol residue. In line with this, MALDI-MS analysis of the 
peracetylated molecule (not shown) showed a displacement of 126 mass units, indicating the 
presence of three alcohol functions. Identification of glycerol monomycolate (GroMM) as a 
novel antigen was supported by 1D 1H NMR analysis (Figure 15E and 15D). 
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Figure 15: Structure determination of natural M. bovis BCG GroMM (D and E), synthetic 
(S)-1-O-mycoloyl-glycerol (C), and (R)-1-O-mycoloyl-glycerol (B) by 1H NMR analysis. 
Specific GroMM protons signals are annotated a to k and are assigned on the structure of the 
major forms of M. bovis BCG GroMM, i.e. esterified by ketomycolic acids, presented in (A). 
n1=19, 21 or 23; n2 and n4= 15, 17 or 19; n3=12 to 17; glycerol protons signals are annotated 
a to c. In (B) and (C), R corresponds to mycolic acid. NMR analysis was done by 
collaborators. 
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The resonances typical of mycolic acids were assigned according to published studies [422-
424]. Protons d (δ 2.31) and e (δ 3.53, multiplet), which correlate together on the 2D 1H-1H 
correlation spectroscopy (COSY) spectrum (not shown), were assigned to the protons of the 
carbons carrying the α-chain and the β-hydroxyl group, respectively (Figure 15A). The 
protons j (δ 2.41, multiplet) and k (δ 0.92, doublet), which also correlate together on the 
COSY spectrum, were assigned to the -CHCH3- group in the distal portion of the 
meromycolic chain. The signal l (δ 0.75, triplet) was assigned to the protons of the terminal 
methyl groups of the α- and meromycolic chain. The multiplets at δ -0.46, δ 0.44 and δ 0.52 
(labeled h), that correlate together on the COSY spectrum, are the characteristic signals of the 
cyclopropanic function protons. Signals around 5 parts per million (ppm) (g at δ 5.16 and f at 
δ 4.83) correspond to olefinic protons, indicating that a small proportion of the mycoloyl 
chains contain ethylenic groups. Protons a (δ 4.11, 4.06 and 3.99), b (δ 3.75) and c (δ 3.47) 
(Figure 15D), which correlate together on the 2D 1H-1H homonuclear Hartmann-Hahn 
(HOHAHA) spectrum (not shown), were assigned to glycerol protons (Figure 15A). 
However, protons a were divided into two independent spin systems, a1 (δ 4.11 and 3.99) 
and a2 (δ 4.06) (Figure 15D), whose definitive assignment was made by NMR analysis of 
synthetic GroMM analogs. 
 
  Stimulation of T cells by hemi-synthetic GroMM (sGroMM) 
 
 To confirm GroMM antigenicity, analogs were chemically synthesized (Figure 16) 
using mycolates isolated from M. tuberculosis H37Rv (figure 17B). 
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Figure 16: Synthesis scheme of (S)-1-O-mycoloyl-glycerol and (R)-1-O-mycoloyl-glycerol. 
Synthesis was done by collaborators. 
 
The chemical synthesis was started using (R)- and (S)-isopropylidene-glycerol, activated by 
p-toluene-sulfonyl [425] (Figure 16). The esterification of glycerol by mycolic acids was 
realized by heating (R) or (S)-isopropylidene-glycerol in the presence of potassium mycolates 
[426]. Both isopropylidene-mycoloyl-glycerol isomers were then deprotected under acidic 
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conditions giving synthetic (R)- or (S)-GroMM (s(R)-GroMM and s(S)-GroMM, 
respectively). The MALDI mass spectra of both sGroMM (Figure 17A) were in agreement 
with the expected mass distribution of GroMM bearing M. tuberculosis H37Rv mycolic acids 
(Figure 17B). 
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Figure 17: (A) MALDI-Tof-MS analysis in positive mode of synthetic GroMM. (B) 
MALDI-Tof-MS analysis in positive mode of the M. tuberculosis H37Rv mycolic acids used 
for synthesis. (C) Estimated masses of sodium adducts corresponding to expected mycolic 
acids and subsequent GroMM. MALDI-Tof-MS analysis was done by collaborators. 
 
Both sGroMM were then analysed by 1D 1H NMR (Figure 15B and 15C). The analysis of 
the (S)-1-O-mycoloyl-glycerol (s(S)-GroMM) showed a protons (designated a1) with 
chemical shifts at 4.00 and 4.12 ppm (Figure 15C), while the analysis of the (R)-1-O-
mycoloyl-glycerol (s(R)-GroMM) showed a protons (designated a2) resonating at 4.05 ppm 
(Figure 15B). These data allowed us to conclude that natural GroMM, which shows a1 and 
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a2 resonances of similar intensity (Figure 15D), is composed of both stereoisomers in equal 
proportions. When these analogs were used to stimulate Z5B71 T cells, s(R)-GroMM was 
more active than s(S)-GroMM, and the natural compound had an intermediate activity 
(Figure 18). 
 
 
 
Figure 18: Immunogenicity of hemi-synthetic GroMM. In C32 or C80 s(S)- or s(R)-GroMM, 
C32 corresponds to corynomycolic acids and C80 to mycolic acids, (S) corresponds to (S)-1-
O-mycoloyl-glycerol and (R) to (R)-1-O-mycoloyl-glycerol. IFNγ release was used to 
quantify T cell activation and is expressed as the mean ng/mL (± SD; n=3). The data are 
representative of three independent experiments. 
 
These data confirmed both nature and structure of the natural antigen, and show that one 
diastereoisomer is preferentially recognized by the TCR of Z5B71 T cells. 
 
  Structural requirements of GroMM for immunogenicity 
 
 Free mycolates may form stimulatory complexes with CD1b [176, 179]. However, 
mycolates and corynomycolates tested in our assay did not activate Z5B71 T cells (not 
shown), highlighting the crucial role of the glycerol moiety for TCR recognition. Acetylation 
of the hydroxyl groups of glycerol was then carried out to evaluate the importance of the 
alcohol functions. The presence of an acetyl substituent on the position c of glycerol (Figure 
15A) did not abolish T cell reactivity, but the presence of two acetyl substituents (on both 
positions b and c) did (Figure 19A). These data suggest that the hydroxyl group in position b 
is implicated in recognition by T cells. GroMM was also submitted to periodic acid cleavage 
and reduction, in order to generate glycol-monomycolate, and this compound showed a 
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drastically reduced ability to stimulate T cells (Figure 19A), demonstrating the importance of 
the position c. We next investigated whether other natural mycolate derivatives were able to 
stimulate Z5B71 T cells. Interestingly, GlcMM, another lipid antigen presented by CD1b 
[179], was able to activate this T cell clone (Figure 19B). 
 
A 
 
B 
 
 
Figure 19: (A) Importance of the alcohol functions of the glycerol head on T cell 
stimulation. Position c was acetylated alone, or both b and c were acetylated. (B) 
Immunogenicity of M. bovis BCG mycolate derivatives. IFNγ release was used to quantify T 
cell activation and is expressed as the mean ng/mL (± SD; n=3). The data are representative 
of three independent experiments. 
 
However, neither trehalose-monomycolate (TMM) nor trehalose-dimycolate (TDM) were 
stimulatory (Figure 19B). The importance of the number and the structure, in particular the 
length, of the acyl chain(s) on the glycerol unit was investigated by testing the 
immunogenicity of different commercial glycerides. Mono-, di- and triglycerides bearing 
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conventional palmitic acids did not stimulate Z5B71 T cells (not shown). Hemi-synthetic 
GroMMs were prepared using corynomycolates (i.e. C32 mycolic acid) isolated from C. 
glutamicum. Even at high doses, T cell stimulation with both R and S isomers was very 
inefficient (Figure 18). However, GlcMM isolated from C. glutamicum (i.e. with 
corynomycolates) showed about the same activity as M. phlei GlcMM (i.e. with C80 mycolic 
acid) (Figure 20). 
 
 
 
Figure 20: Immunogenicity of GlcMM from C. glutamicum and M. phlei. IFNγ release was 
used to quantify T cell activation and is expressed as the mean ng/mL (± SD; n=3). The data 
are representative of three independent experiments. 
 
Collectively, these results show that both fatty acid and hydrophilic head influence 
stimulation of Z5B71 T cells. 
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  Presentation of GroMM is CD1b-restricted and 
CD1e-independent 
 
 To determine GroMM restriction, we used CD1-transfected APCs. Only APCs 
expressing CD1b were stimulatory (Figure 21). 
 
 
 
Figure 21: Presentation of GroMM to Z5B71 T cells by CD1-transfected THP-1 cells. TNFα 
release was used to quantify T cell activation and is expressed as the mean ng/mL (± SD; 
n=3). The data are representative of three independent experiments. 
 
In addition, the stimulation was inhibited by anti-CD1b blocking monoclonal antibodies 
(mAbs), but not by other anti-CD1 mAbs (Figure 22). 
 
 
 
Figure 22: mAbs-mediated inhibition of T cell activation. TNFα release was used to quantify 
T cell activation and is expressed as the mean ng/mL (± SD; n=3). The data are representative 
of three independent experiments. 
 
Since CD1e may facilitate presentation of complex mycobacterial lipids [34], we investigated 
whether GroMM antigenicity is influenced by CD1e. Similar T cell responses were observed 
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using APCs expressing only CD1b or both CD1b and CD1e (Figure 23), thus demonstrating 
that CD1e is not required for presentation of GroMM to T cells. 
 
 
 
Figure 23: Presentation of GroMM to Z5B71 T cells is CD1e-independent. THP-1-CD1b 
() and THP-1-CD1b-CD1e () cells were used as APCs. IFNγ release was used to quantify 
T cell activation and is expressed as the mean ng/mL (± SD; n=3). The data are representative 
of three independent experiments. 
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  M. tuberculosis-infected DCs stimulate Z5B71 T cells 
 
 To determine whether mycobacterial lipids stimulating Z5B71 T cells are antigenic 
during the course of the infection, we pulsed human DCs with heat-killed M. tuberculosis and 
found strong activation (Figure 24). 
 
 
 
Figure 24: Activation of Z5B71 T cells by human DCs pulsed with heat-killed M. 
tuberculosis. IFNγ release was used to quantify T cell activation and is expressed as the mean 
pg/mL (± SD; n=3). The data are representative of three independent experiments. 
 
As Z5B71 T cells were reactive, we then infected human DCs with M. tuberculosis (Figure 
25). 
 
 
 
Figure 25: Activation of Z5B71 T cells by human DCs infected with living M. tuberculosis. 
IFNγ release was used to quantify T cell activation and is expressed as the mean ng/mL (± 
SD; n=3). The data are representative of three independent experiments. 
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Infected APCs were also able to stimulate GroMM-specific T cells, confirming the 
immunogenicity of these antigens during infection. These data also confirm that GroMM 
forms immunogenic complexes with CD1b upon phagosomal internalization of bacteria. 
 
GroMM-reactive T cells are not detected in patients 
with active tuberculosis 
 
 The next step was to determine whether T cells in the peripheral blood of human 
donors recognize GroMM. We collected blood samples from patients classified as naïve (or 
purified protein derivative (PPD)-negative) (n=10), with latent M. tuberculosis infection 
(n=19), BCG-immunized (n=22), and with active M. tuberculosis infection (n=11). Then, we 
measured IFNγ release after stimulation with GroMM. Significant responses were observed 
with the blood from BCG-immunized donors and donors with latent infection (Figure 26). 
However, no responses were observed with the blood from naïve donors and donors with 
active tuberculosis (Figure 26), although the ones with active tuberculosis vigorously 
responded to PPD (not shown). 
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Figure 26: GroMM reactivity of naïve donors (n=10), donors with latent M. tuberculosis 
infection (n=19), BCG-immunized donors (n=22), and donors with active M. tuberculosis 
infection (n=11). Black circles show individual donors, horizontal bars represent the average 
for each group. One asterisk indicates a confidence interval greater than 95%. A confidence 
interval below 95% was considered insignificant. IFNγ release was used to quantify T cell 
activation and is expressed as the mean pg/mL. GroMM reactivity of donors was assessed by 
collaborators. 
 
We also verified the CD1-retriction of the reactive T cells, and a cocktail of blocking 
antibodies directed against group 1 CD1 molecules inhibits GroMM-induced IFNγ secretion 
(Figure 27). In contrast, anti-MHC class I antibodies were not inhibitory (not shown). 
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Figure 27: Inhibition of T cell activation by anti-CD1 mAbs for ten PPD-positive healthy 
donors. Black circles show individual donors, horizontal bars represent the average for each 
group. Two asterisks indicate a confidence interval greater than 99%. A confidence interval 
below 95% was considered insignificant. IFNγ release was used to quantify T cell activation 
and is expressed as the mean pg/mL. Inhibition of T cell activation using blood from donors 
was assessed by collaborators. 
 
The specificity of the ex vivo lipid reactivity was addressed testing the reactivity of five PPD-
reactive donors to three unrelated mycobacterial lipids: GroMM, PIM2 and DAT (Figure 28). 
One donor responded only to DAT, two responded only to GroMM, one only to PIM2, and 
one to both GroMM and DAT. This indicates that the ex vivo T cell responses are specific for 
individual lipids and not due to cross-reactivity. 
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Figure 28: Ex vivo T cell responses are specific for individual lipid antigens. Each donor is 
represented by a bar, and reactivity to three unrelated mycobacterial lipids (GroMM, PIM2 
and DAT) was assessed. IFNγ release was used to quantify T cell activation and is expressed 
as the mean pg/mL. Lipid reactivity of donors was performed by collaborators. 
 
Altogether, these data show that GroMM-specific T cells are expanded after mycobacterial 
infection and are no longer detectable during active disease. 
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 Discussion 
 
 The mycobacterial envelope contains a large number of diverse lipid molecules. 
Among them, CD1-restricted antigens have been identified, which are represented by: i) 
mycoloyl-based molecules, such as free mycolic acids [176] and GlcMM [179]; ii) mannosyl-
phosphatidylinositol-based glycolipids represented by LAMs [180], LMs [180], and PIMs 
[34, 188]; iii) sulfoglycolipids [178]; iv) lipopeptides [177]; and v) polyketides [181]. 
Here, we identified GroMM as a mycoloyl-based lipid antigen presented by CD1b. GroMM 
is thought to be inserted in the outer part of the mycomembrane and is present in many 
mycobacterial species, including M. bovis BCG [427], M. tuberculosis [428-430], but also 
Nocardia, Corynebacteria, and Gordona bacterial cells [431]. 
Hemi-synthesis of GroMM analogs, (R)-1-O-mycoloyl-glycerol (s(R)-GroMM) and (S)-1-O-
mycoloyl-glycerol (s(S)-GroMM), allowed us to assess structural contributions to 
immunogenicity. Both diastereoisomers stimulated Z5B71 T cells, s(R)-GroMM being more 
active than s(S)-GroMM. Shortening the mycolic acid chain almost abrogated 
immunogenicity of the GroMM analogs, in line with previous studies showing that GlcMM 
with long alkyl chains (C80) requires internalization and trafficking through late endosomal 
compartments for efficient presentation whereas GlcMM with short alkyl chains (C32) can be 
loaded onto CD1b on the cell surface [25]. The fact that Z5B71 T cells react to both GlcMM 
and GroMM argue for the presence of a common epitope. By chemical degradation, we found 
that GroMM corresponds to the minimal structure required for recognition by Z5B71 T cells, 
raising the question of how cross-reactivity between these two lipids may occur. The crystal 
structure of GlcMM bound to CD1b [432] shows that the arginine in position 79 of the α1 
helix (R79) of CD1b makes a hydrogen bond with the oxygen of the alcohol function on the 
C4 of glucose (Figure 29A), possibly stabilizing a specific orientation of the sugar. 
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Figure 29: Models resulting from molecular modeling calculations for CD1b-GlcMM (A) 
and CD1b-GroMM (B) complexes. The resulting structures were superimposable (C), with 
glycerol well superposed on a part of the glucosidic ring. Both glucose and glycerol are found 
in close contact with R79. Molecular modeling was done by collaborators. 
 
Superimposition of GroMM and GlcMM structures shows that the hydroxyl in position c of 
GroMM might correspond to OH-4 of the glucosyl unit of GlcMM, whereas the hydroxyl in 
position b, corresponding to the oxygen atom of the sugar ring, might be available for a 
cognate interaction with the TCR (Figure 29B and 29C). This model might explain the 
recognition of both GlcMM and GroMM structures by the Z5B71 T cell clone. Using these T 
cells, we also found that the mycolic acid length is important for stimulation by GroMM, but 
less for stimulation by GlcMM. The current paradigm is that fatty acyl chain length affects 
positioning of the polar head and its subsequent interaction with the TCR [25, 190, 307, 432]. 
This parameter might be more critical for GroMM because the number of possible 
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interactions with the TCR is more limited with glycerol than with glucose. Taken together, 
these data suggest that mycolic acids may constitute a scaffold for lipidic antigens, which 
supports binding to CD1b and facilitates interaction of different polar heads with the TCR. 
This resembles the scaffold nature of ceramide and diacylglycerol moieties found with other 
lipid antigens [433, 434], and thus reveals a more general rule in which scaffold molecules 
which are well suited for CD1 binding confer immunogenicity to a large number of lipid 
molecules. 
The observation that GroMM, GlcMM and free mycolic acid are all presented by CD1b 
molecules is probably caused by the unique presence of intricate and connected hydrophobic 
pockets in CD1b. Crystallographic data have revealed how the meromycolate chain of 
GlcMM completely occupies the A’ T’ and F’ channels of CD1b and protrudes out of the F’ 
channel, possibly interacting with the TCR, whereas the α-chain occupies the C’ channel 
[432]. In addition, CD1b traffics through the phagosome [435] and might facilitate formation 
of immunogenic complexes with mycobacterial lipid antigens released in the phagosomes. 
CD1b binds and present C80 lipidic antigens using a pH-dependent mechanism [169] and 
does not require cellular enzymes or lipid cleavage [436]. In the latter study, it has been 
proposed that lipids with long acyl chains are loaded in an intact form, and protrude through a 
portal near the bottom of the CD1b groove. Although we cannot formally exclude that the 
meromycolate chain of GroMM is partially degraded before forming antigenic complexes 
with CD1b, it is more likely that it is stimulatory in its native form. This is supported by the 
fact that GroMM analogs with short fatty acids are poorly immunogenic. In addition, GroMM 
from M. bovis BCG is still immunogenic when presented by APCs lacking CD1e, a CD1 
family member involved in processing of complex glycolipid antigens [34]. 
GroMM stimulates T cells in the peripheral blood of human donors that were BCG-
immunized or with latent M. tuberculosis infection. However, no stimulation is observed in 
the case of patients with active M. tuberculosis infection. This contrasts with the response to 
Ac2SGL, which is detectable in donors with both latent and active M. tuberculosis infection 
[178]. Several hypothesis might explain why patients with active M. tuberculosis infection 
failed to respond to GroMM. One could be that in investigated patients a general and non-
specific tumor growth factor (TGF)-β-mediated immune suppression prevents in vitro 
response, as described for the initial phase of the acute disease [437]. However, this is 
unlikely as T cell responses to mycobacterial protein antigens were readily detectable in the 
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peripheral blood of the same donors. It is also possible that GroMM-specific T cells are 
sequestered in inflamed tissues, as suggested for Ag85-specific CD8+ T cells [438]. A third 
possibility is that GroMM-specific T cells participate in protection and limit growth of the 
bacilli. The absence of these T cells might then directly contribute to appearance of clinically 
active disease. The fact that GroMM-specific T cells recognize mycobacteria-infected cells 
and release pro-inflammatory cytokines are in accordance with this hypothesis. Evaluation of 
the protective value of GroMM will shed light on its putative use in subunit vaccine 
formulations against tuberculosis. 
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CHAPTER 2 
 
 
Fatty acyl structures of Mycobacterium tuberculosis sulfoglycolipid 
govern T cell immunogenicity 
 
(These results have been submitted to the Journal of Immunology) 
 
 According to crystal structures of CD1:mycobacterial lipid complexes, it is thought 
that acyl appendages are used to anchor lipids to the CD1 proteins, thus providing a correct 
conformation and facilitating contact between the hydrophilic part of the lipids and the TCR 
[439]. As described before (see Figures 1, 2, and 3), the human CD1a antigen-binding 
groove is composed of two pockets, A’ and F’ [41]; whereas the human CD1b groove is 
compartimentalized in three pockets, A’, C’ and F’, directly accessible from the surface, plus 
the T’ tunnel that interconnects the A’ and F’ pockets, leading to a 70 Å-long superchannel 
[39]. This T’ tunnel, unique to CD1b, arises from substitution at positions 98 and 116 of 
bulky residues by glycine residues, compared to other CD1 isoforms. The C’ pocket is, 
seemingly, also unique to CD1b. This large antigen-binding cavity may allow optimal 
accommodation of antigens with an overall lipid length of C62-C65 onto CD1b [40]. The two 
acyl chains of Ac2SGL antigens, i.e. a palmitoyl (or stearoyl) and a C26-C40 
hydroxyphtioceranoic acid (a dextrogyre multimethyl-branched fatty acid [178]) (Table I), fit 
within the CD1b groove and seem to accommodate in the C’ pocket and the A’-T’-F’ 
channel, respectively. Indeed, it was suggested from the crystal structure of the 
CD1b:GlcMM complex that the C49 meromycolic chain fully occupied the A’-F’-T’ 
superchannel, whereas the C8 α-chain only partially filled the C’ channel [432]. Mapping of 
the CD1b:GlcMM molecular determinants responsible for recognition by T cells supported a 
critical role for the hydrophilic cap, whereas the length and structure of the acyl chains 
seemed of lesser importance [179, 190]. However, microbial and host glycolipids do share 
identical polar moieties, still suggesting that acyl appendages may allows some kind of 
discrimination. 
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As Ac2SGLs may represent ideal candidates for novel subunit lipid vaccines, we performed a 
detailed investigation of the acyl chains structural requirements contributing to Ac2SGL 
immunogenicity by using synthetic SGL analogs (Table I). 
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Table I: Structure of the M. tuberculosis sulfoglycolipid (Ac2SGL) and the synthetic SGL 
analogs. R and R’ numbers under brackets correspond to the number of methylene units of 
the aliphatic linear chain. For Ac2SGL, R’ corresponds to the most abundant homologue. 
Mono-, di- and trimethyl-branched fatty acids are pure stereoisomers, while unsaturated tetra 
and penta are 88% and saturated tetra is 83%. R and S correspond to the configuration of the 
respective chiral center. 
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 Results 
 
  Synthesis of diacylated SGLs with linear fatty acids 
 
 Ac2SGLs are glycolipid antigens synthesized by virulent M. tuberculosis strains and 
stimulate CD1b-restricted αβ T cells [178]. The hydrophilic part is composed by a 2’-O-
sulfate-α,α-D-trehalose acylated on position 2 with a palmitic or stearic acid, and on position 
3 with a hydroxyphtioceranoic acid (Table I). The most abundant hydroxyphtioceranoic 
homologue is a dextrogyre 32 carbon atoms long chain with 8 C-methyl branched groups; all 
C-methyl bearing stereocenters belonging to the L series [440]. To determine whether this 
unique hydroxyphtioceranoil residue is important for stimulation of specific T cells, a 
chemical approach was developed (Figure 30) in order to synthesize a series of SGLs in 
which the hydroxyphtioceranoic acid had been replaced by linear fatty acids such as palmitic 
(C16) (SGL1), 16-hydroxypalmitic (SGL2) and melissic acid (C30) (SGL3) (Table I). 
 
 
 
Figure 30: General route for synthesis of SGLs. The synthesis is based on a 7-step reaction 
sequence (1 to SGL) with an overall product yield of about 5%. Synthesis was done by 
collaborators and is described in Materials and Methods. 
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Palmitoyl-sulfoglycolipids with an additional linear fatty 
acyl-chain bind to soluble human CD1b 
 
 To investigate the immunogenicity of synthetic SGLs, we first monitored their 
binding in vitro to soluble human CD1b (shCD1b) expressed in mouse cells. The shCD1b 
showed one major band in gel IEF electrophoresis (Figure 31A), and one peak in the 
capillary IEF (cIEF) electrophoregram (Figure 31B). These forms were assigned to shCD1b 
loaded with endogenous chaperon lipids including PC and a C41-44 spacer lipid [133]. 
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Figure 31: (A) IEF gel analysis of SGL binding onto shCD1b. Incubation of shCD1b and 
SGL was done in the absence (a) or presence (b) of taurocholate. Proteins were revealed by 
Coomassie R350 staining. (B) Illustrative electrophoregrams (UV 280 nm) corresponding to 
shCD1b incubated in the absence or presence of Ac2SGL, SGL3 or SGL9; in the presence of 
taurocholate. IS, internal standard; the second peak corresponds to shCD1b without SGL, the 
third peak corresponds to shCD1b loaded with negatively-charged SGL. IEF and cIEF were 
done by collaborators. 
 
Incubation of shCD1b with Ac2SGL resulted in the appearance of a second band in IEF 
tentatively assigned to the shCD1b:Ac2SGL complexes. cIEF electrophoregram analysis of 
shCD1b incubated with Ac2SGL in presence of detergent showed an additional peak at higher 
migration time, thus supporting the formation of shCD1b:Ac2SGL complexes as well. The 
difference in electrophoretic behavior compared with native shCD1b arises from the 
modification of the isoelectric point caused by displacement of the neutral endogenous ligand 
PC by negatively charged Ac2SGL. Integration of the electrophoregram peak revealed that 
70% of shCD1b was complexed with Ac2SGL (Figure 32). 
a 
b 
 89 
 
 
 
Figure 32: SGL binding onto shCD1b. shCD1b was incubated with the SGLs in presence of 
taurocholate, followed by cIEF analysis. The peaks assigned to shCD1b and shCD1b:SGL 
complexes were integrated and used to determine the percentage of shCD1b loaded with 
SGLs. 
 
Similarly, IEF methods were used to determine the percentage of shCD1b molecules loaded 
with other SGLs. SGL1 and SGL2, with short linear acyl chains consisting of palmitic and 
16-hydroxypalmitic acids at position 3 (Table I), formed similar amounts of shCD1b:SGL 
complexes (60-80%), resembling the natural Ac2SGL (Figures 31A and 32). In contrast, very 
inefficient binding of C30-acylated SGL3 was observed (~20%), irrespective of the presence 
or absence of detergent during loading (Figures 31A and 32). 
 
  SGL analogs with linear fatty acyl chains are not stimulatory 
 
 The stimulatory activity of the synthetic SGLs was evaluated in a classical T cell 
stimulation assay using human DCs as APCs. Ac2SGL-specific T cells were reactive to 
Ac2SGL, but not to SGL1, SGL2, or SGL3 (Figure 33A). 
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Figure 33: Immunogenicity of SGLs. Human DCs were pre-incubated with different 
concentrations of natural Ac2SGL or synthetic SGLs before addition of T cells. GM-CSF 
release was used to quantify T cell activation and is expressed as the mean ng/mL (± SD; 
n=3). Each panel shows the T cell response to different SGL analogs. The data are 
representative of three independent experiments. 
 
Since SGL1 and SGL2 efficiently bind to shCD1b, their lack of immunogenicity might be 
due to the absence of branched C-methyl groups on the aliphatic chain. 
 
Hemisynthetic SGLs containing M. tuberculosis mycolipenic 
and mycosanoic acids are immunogenic 
 
 To assess the role of C-methyl groups substituting the fatty acyl chain, hemisynthetic 
SGLs containing M. tuberculosis mycolipenic and mycosanoic acyl chains were prepared. 
Dextrogyre di- and tri-methyl branched fatty acids, such as mycosanoic and the α,β-
unsaturated mycolipenic acids are present in the envelope of M. tuberculosis as acyl 
substituents of di-, tri-, and penta-acylated trehalose (DAT, TAT, and PAT, respectively) 
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[441]. A mixture of these fatty acids, containing also conventional fatty acids, was obtained 
by alkaline hydrolysis of M. tuberculosis DAT and TAT, and introduced in position 3 of 2-O-
palmitoyl-α,α-D-trehalose derivative 3 following the general strategy depicted in (Figure 
30). The structure of the resulting hemisynthetic SGL4 was supported by 1H NMR (not 
shown) and MALDI-Tof-MS (Figure 34) and appeared as a mixture of C22 mycosanoic and 
C24 mycolipenic acid-substituted sulfoglycolipids (m/z 1009.5, m/z 1049.6). 
 
 
 
Figure 34: MALDI-Tof-MS analysis in positive mode of the semi-synthetic sulfoglycolipid 
analog SGL4. Peaks with * correspond to SGL4 with unsaturated mycolipenic acids (Table 
I); m/z 1009.5 typifies SGL4 with C22 mycosanoic acid; m/z = 897.4, 925.5 and 939.5 
correspond to SGL4 with two palmitic acids, one palmitic and one stearic, one palmitic and 
one tuberculostearic, respectively. MALDI-Tof-MS analysis was done by collaborators. 
 
SGL4 mass spectrum also showed the presence of SGLs acylated by conventional C16/C16 
(m/z 897.4), C16/C18 (m/z 925.5) and C16/C19 (m/z 939.5) fatty acids. SGL4 was 
immunogenic, although less than natural Ac2SGL (Figure 33A). The lower activity of SGL4 
might be attributed to the presence of non-antigenic forms containing conventional fatty 
acids. These data are in line with our hypothesis, strongly suggesting that branched methyl 
groups are required to confer immunogenicity to SGLs. 
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The number of C-methyl branched groups controls the 
antigenicity of the SGL analogs 
 
 To test whether the number of methyl-branched acyl appendages influence 
immunogenicity, dextrogyre multimethyl-branched saturated and α,β-monounsaturated fatty 
acids were synthesized and coupled to 2-O-palmitoyl-α,α-D-trehalose derivative 3 (Figure 
30), leading to the corresponding SGLs (Table I). Binding of each SGL analog onto shCD1b 
was investigated by IEF (Figure 31A and 31B) and compared to that of Ac2SGL. SGL5, 
SGL6, SGL7, and SGL8, containing respectively saturated fatty acids with one, two, three, 
and four C-methyl branched groups, showed efficient binding onto shCD1b, from 54% to 
64% (Figure 32). In contrast, SGL9 to SGL13 analogs, that are characterized by the presence 
of α,β-unsaturated fatty acids, formed less complexes with shCD1b as the number of 
branched methyl groups increased. cIEF analysis confirmed a drop from 80% to 50% when 
the number of C-methyl groups increased from 1 to 5 (Figure 32). The SGL analogs 
esterified with saturated fatty acids were immunogenic when the number of C-methyl groups 
was equal to two (SGL6), and immunogenicity drastically increased with four methyl groups 
(SGL8) (Figure 33B). Also in the case of unsaturated SGLs, immunogenicity was observed 
with two methyl groups (SGL10), and increased progressively with three and four methyl 
groups (SGL11 and SGL12, respectively) (Figure 33C). Therefore, a direct correlation was 
observed between the immunogenicity of the SGL analogs and the number of C-methyl 
groups that substitute the aliphatic tail at the position 3 of the trehalose core. SGL13, which 
contains 5 branched methyl groups, showed exactly the same stimulatory capacity as SGL12 
(Figure 33C), suggesting that the presence of additional branched methyl groups attached at 
carbons after C-8 does not improve antigenicity. SGL12, which is characterized by the 
(4S,6S,8S)-2,4,6,8-tetramethyltetracos-2-enoyl appendage, and SGL13, by the 
(4S,6S,8S,10S)-2,4,6,8,10-pentamethylhexacos-2-enoyl appendage, were the most 
immunogenic synthetic SGLs. It should also be noticed that the SGL analogs with α,β-
unsaturated fatty acids were more immunogenic than the corresponding ones with saturated 
fatty acids, despite the fact that the hydroxyphtioceranoic acid of the natural Ac2SGL is a 
saturated one (Figure 33B and 33C). SGL12 and SGL13 showed similar efficacy, if not 
better, to that of Ac2SGL since all three lipids induced release of similar high amounts of 
GM-CSF by T cells (Figure 35A). However, both SGL12 and SGL13 were less potent than 
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Ac2SGL since higher doses were necessary to induce half maximal cytokine release. These 
effects are clearly depicted by the Lineweaver-Burk plot of the same data (Figure 35B), 
where all three lipids cross the efficacy axis (y axis) at close intercepts, whereas they are 
separated on the potency axis (x axis). 
 
 
 
Figure 35: Immunogenicity of synthetic SGLs containing an α,β-unsaturated multimethyl 
aliphatic chain in position 3 of the trehalose core. (A) Human DCs were pre-incubated with 
different concentrations of natural Ac2SGL or synthetic SGLs before addition of T cells. 
GM-CSF release was used to quantify T cell activation and is expressed as the mean ng/mL 
(± SD; n=3). The data are representative of three independent experiments. (B) Lineweaver-
Burk plot comparing efficacy (y axis intercept) and potency (x axis intercept) of Ac2SGL, 
SGL12, and SGL13. 
 
These findings indicate that the branched methyl decorations of the acyl chain located at the 
position 3 of the SGL’s trehalose core govern T cell stimulation. 
 
The length of the conventional acyl chain located at the position 2 
of the trehalose core modulates SGL antigenicity 
 
 To get further insights into the role of the acyl appendages for TCR recognition, we 
studied whether the length of the acyl chain located at position 2 of the trehalose unit would 
affect the binding onto shCD1b and/or T cell recognition. Two other SGL analogs with C8 
(SGL14) and C24 (SGL15) linear acyl chains on position 2 were synthesized. These SGLs 
share the same (4S,6S,8S)-2,4,6,8-tetramethyltetracos-2-enoyl appendage at position 3 
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(Table I). Substitution of C16 by C24 acyl chain led to a drastic reduction in binding onto 
shCD1b, with only 20% of shCD1b:SGL15 complexes formed (Figure 32). On the contrary, 
substitution by C8 acyl chain resulted in 50% of shCD1b:SGL14 complexes formed. In 
addition, possibly as a consequence, stimulation of Ac2SGL-specific T cells with SGL15 was 
very weak, whereas SGL14 was active, albeit less than SGL12 (Figure 33D). The 
unexpected low binding of SGL15 onto shCD1b probably reflects the difficulty to 
accommodate one of the two C24 aliphatic chains attached either at position 2 or 3 of the 
trehalose head inside the C’ channel of CD1b. A C24 long acyl chain might prevent insertion 
inside the C’ pocket of CD1b. To test this hypothesis, we synthesized another SGL analog 
(SGL16) with a C22 acyl chain at position 2 (dimethyldocos-2-enoyl acyl) and a C16 
(palmitoyl acyl) at position 3 (Table I). SGL16 was then compared to SGL10, acylated by 
the same fatty acids but at the conventional position (Table I). Up to 80% of shCD1b formed 
complexes with SGL16 (Figure 32), showing that swapping the short with the long acyl 
appendages in position 2 and 3 did not alter binding to CD1b. However, SGL16 was not 
immunogenic (Figure 33D). These findings can be explained by the capacity of the C22 long 
chain at position 2 to accommodate inside the A’-T’-F’ superchannel and the C16 at position 3 
to insert into the C’ channel. As a consequence, the SGL16 trehalose-sulfate epitope probably 
rotates by 180° compared to its position in complexes involving Ac2SGL, and is not capable 
of engaging the specific TCR anymore (Figure 36). 
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Figure 36: Schematic drawings of CD1b:SGL complexes interacting with the specific TCR. 
(A) CD1b:SGL10 complex forming stimulatory interactions with the TCR. (B) CD1b:SGL16 
complex unable to form stimulatory interactions. SGL10 and SGL16 have the same acyl 
chains, but in permuted positions. The drawing shows insertion in the C’ pocket of the C16 
acyl chain attached to either C2 (in SGL10) or to C3 (in SGL16). This allows both SGLs to 
bind shCD1b. However, only SGL10 forms the stimulatory complex interacting with the 
TCR. 
 
Taken together, these data demonstrate that SGL analogs are immunogenic when they carry 
an aliphatic chain equal to, or shorter than C18 (stearoyl acyl) at position 2 of the trehalose 
core, and when they carry a long multimethyl-saturated chain, or α,β-unsaturated fatty acyl 
appendage, at position 3. In addition, the length of fatty acid chains at positions 2 and 3 of the 
trehalose core might select the CD1b channel (A’-T’-F’ vs. C’) to fill, thus controlling the 
orientation of the polar head. 
 
The absolute configuration of the C-methyl branched chiral 
carbons is sensed by the TCR 
 
 Hydroxyphtioceranoic acids are dextrogyre multimethyl-branched saturated fatty 
acids [441, 442]. To better define the contribution of the chiral carbon stereochemistry to T 
cell recognition, we synthesized the analog SGL17 (Table I) by coupling the levogyre (R)-
2,4-dimethyldocos-2-enoic acid at position 3 of 2-O-palmitoyl-α,α-D-trehalose derivative 3 
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(Figure 30). The only structural difference between SGL17 and SGL10 is the absolute 
configuration of the chiral carbon of the acyl chains at position 3 of the trehalose core. 
Binding onto shCD1b was similar for both SGL analogs (Figure 32), but only SGL10 was 
stimulatory (Figure 33D). These data demonstrate that the configuration of the aliphatic 
chiral carbons affects TCR recognition. 
 
Stimulation of Ac2SGL-specific T cells by plate-bound 
shCD1b:SGL complexes 
 
 Differences in antigen trafficking to late endosomes [179] or in loading onto CD1b 
molecules in vivo may affect immunogenicity. The reduced potency of the most active 
synthetic analogs, compared to natural Ac2SGL, as well as lack of activity of analogs that 
proved capable of binding to shCD1b in vitro, might then be ascribed to events occurring in 
living APCs. To exclude such possibilities, we investigated the stimulatory capacity of plate-
bound shCD1b:SGL complexes. Plate-bound shCD1b complexed with Ac2SGL induced 
strong T cell activation (Figure 37), whereas control groups stimulated with unloaded 
shCD1b or without shCD1b were not activated, thus confirming the antigen-specificity of the 
T cell response. 
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Figure 37: Stimulatory capacity of shCD1b:SGL complexes. Complexes were coated on 96 
well plates before addition of T cells. GM-CSF release was used to quantify T cell activation 
and is expressed as the mean ng/mL (± SD; n=3). The data are representative of three 
independent experiments. 
 
The shCD1b complexes formed with SGL8, SGL10, SGL12 and SGL13 were as active as 
Ac2SGL, whereas SGL7 and SGL11 were less active than the natural compound (Figure 37). 
When the plate-bound assay results were compared to those obtained with living DCs, the 
shCD1b complexes formed with SGL7, SGL8, SGL11, SGL12 and SGL13 stimulated T cells 
like SGL-pulsed living DCs. SGL10 was more stimulatory in the plate-bound assay than with 
living DCs. Whether this difference is ascribed to more efficient formation of ternary 
complexes in vitro will be subject of future studies. The data obtained with the plate-bound 
assay confirmed: i) lack of immunogenicity of SGL analogs with linear acyl chains; ii) the 
decisive role of the chirality of the fatty acid attached at the position 3 of the trehalose 
(SGL17 vs. SGL10); iii) the TCR sensitivity to length changes on acyl chain at the position 2 
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of the trehalose (SGL14 vs. SGL12); and iv) the dramatic effect of aliphatic tail permutation 
at the position 2 and 3 (SGL16 vs. SGL10). 
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 Discussion 
 
 The diacylated sulfoglycolipid antigen (Ac2SGL) is produced by virulent 
Mycobacteria and stimulates CD1b-restricted T cells [178] with bactericidal activity. 
Ac2SGL is characterized by the presence of dextrogyre multimethyl-branched fatty acids 
assigned, for the most abundant homolog, to C32-hydroxyphtioceranoic acids at the position 3 
of a 2’-O-sulfate-α,α-D-trehalose, the position 2 being acylated by a palmitic or stearic acid 
[178]. We systematically changed the type of aliphatic chains and tested each SGL analog 
using three different assays: i) Loading of SGLs to soluble human CD1b; ii) T cell activation 
with living DCs; and iii) T cell activation with plate-bound recombinant shCD1b. The 
combined evaluation of these tests allowed us to identify three experimentally supported 
rules governing Ac2SGL immunogenicity. 
The first rule is that the type of aliphatic chain is sensed by the TCR. Replacement of the 
hydroxyphtioceranoyl appendage by conventional fatty acids, i.e. palmitic (SGL1) or 
hydroxypalmitic (SGL2), abrogates T cell stimulation, but not binding to CD1b. Replacement 
of the hydroxyphtioceranoyl tail by a linear C30 aliphatic appendage (SGL3) abrogates both 
binding to shCD1b and T cell activation. Thus, irrespective of the chain length (C16 or C30) 
these SGL variants are not immunogenic when presented by professional antigen-presenting 
cells such as DCs. Since SGL1 and SGL2 bind to shCD1b and are not stimulatory, they 
probably do not engage the TCR because the complexes formed with CD1b do not correctly 
expose the trehalose-sulfate epitope that activates T cells. Previous studies provided initial 
evidences that acyl appendages affect T cell stimulation [28, 154, 196] although it was not 
investigated whether binding to CD1 or interaction with the TCR were affected. Other studies 
reported that αGalCer analogs with short chains behave as weak agonists [156] and generate 
complexes with CD1d which interact with low affinity with the TCR [307]. 
The second rule is that the T cell stimulatory activity of Ac2SGL depends on the presence of 
branched-methyl groups on the aliphatic tail at position 3 of the trehalose-sulfate. Indeed, at 
least two C-methyl branches in the fatty acids of SGL analogs are required for 
immunogenicity. A possible explanation is that insertion of ramified chains inside the CD1b 
pocket induces discrete conformational changes of CD1b amino-acid residues directly 
contacting the TCR. The terminal aliphatic C-methyl groups are close to the Ac2SGL 
hydrophilic cap, and presumably contact residues of or beneath the CD1b α1-α2 helices. This 
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assumption is supported by lack of immunogenicity of SGL17 analog, which binds efficiently 
to CD1b and differs from the active SGL10 only in the absolute configuration of the C-
methyl chiral carbon atoms. A previous study investigating T cell response to GlcMM 
reported that presentation of GlcMM to CD1b-restricted T cells is not affected by substantial 
variations in its lipid tail [179]. In the case of GlcMM, the proximal decoration is separated 
from the hydrophilic cap by at least 17 methylene units, and it was proposed that it lays deep 
inside the CD1b hydrophobic pocket [432]. This localization may explain why decorations 
are of lesser importance in the GlcMM-specific T cell responses, whereas they are essential 
in the case of Ac2SGL in which the methyl groups are proximal to the ester bond linking the 
fatty acid to trehalose. This hypothesis is in agreement with the finding that addition of 
further methyl groups beyond 4 to SGL analogs does not enhance T cell response. Indeed, 
SGL13 that contains a fifth branched-methyl group on C-10 is as active as SGL12 that 
contains only four branched-methyl groups. 
The third rule is that the length of the two aliphatic tails dictates in which CD1b pocket they 
will become inserted. The crystal structure of CD1b:SGL suggests that A’ and C’ are filled 
by the SGL acyl appendages (Garcia-Alles et al. manuscript in preparation). The C’ pocket 
appears to behave as a molecular ruler, accommodating aliphatic chains with maximum 
lengths of 16-18 carbons. Thus, SGL10, SGL12 and SGL13, presenting a C16 acyl chain at 
position 2 and C22/C24 at position 3, bind to CD1b and stimulate T cells. On the contrary, 
introduction of a short fatty acid at position 2 of the trehalose (C8, SGL14) preserves binding 
to shCD1b, but dramatically decreases antigenicity. In addition, the presence of two C24-long 
fatty acids at the positions 2 and 3 (SGL15) abolishes both binding to CD1b and T cell 
recognition. This finding confirms that the presence of C16/C18 aliphatic tails at position 2 
appears to be mandatory. This is further supported by the strong CD1b-binding of the 
otherwise inactive SGL16. In SGL16, the acyl chains at positions 2 and 3 are permuted as 
compared to SGL10. The presence of one C16 chain is compatible with insertion into the C’ 
pocket, and with the formation of stable complexes with shCD1b. However, the permuted 
C16 chain might impose a change of the position of the trehalose-sulfate epitope which 
prevents TCR recognition (Figure 36). Overall, these data suggest that the C’ pocket is in a 
closed state, and does not allow accommodation of fatty acid tails longer than C18. This is in 
accordance with the recent crystal structure of natively folded CD1b [133], and contrasts with 
previous crystallographic structures obtained from in vitro refolded CD1b that point to the 
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existence of a C’ portal [39]. Whether in vitro, but not in vivo, refolding causes opening of 
the C’ portal remains to be investigated. The presence of an open C’ pocket was also 
proposed by studies showing that GlcMM with a C24 α-mycolic chain stimulates specific T 
cells without trimming of this acyl chain [436]. These results might be explained with the 
possibility that different lipid antigens differ in the capacity to induce opening of the C’ 
pocket. Alternatively, the GlcMM-specific TCR might recognize the epitope generated by 
incomplete insertion into the C’ pocket, whereas the Ac2SGL-specific TCR might require a 
complete insertion. 
In a recent publication [196], the importance of acyl chains with branched-methyl groups has 
been described for mannosyl β-1-phosphomyketides (MPMs), a group of CD1c-presented 
mycobacterial antigens. Like the response to Ac2SGL, also the response to MPMs is strictly 
dependent on the chiral conformation of the branched-methyl groups. Our data are in line 
with this possibility and extend this type of recognition to CD1b-presented lipid antigens. In 
addition, our findings show that a wrong chiral conformation does not prevent binding to the 
CD1 presenting molecule, but directly affects TCR activation. It should be noticed that 
branched lipids are synthesized by bacterial cells and not by mammalian cells. The fact that 
the immune system also discriminates microbial from host glycolipids by recognizing the 
presence of acyl appendages unique to microbial cells remains an open possibility. The 
present study, combining antigen binding to CD1b and T cell activation assays, aims at 
clarifying the requirements for binding onto the antigen-presenting molecule and for 
productive TCR engagement. These informations are of primary importance for the design of 
strong agonist lipid molecules to be used as subunit vaccines in tuberculosis. Chemical 
synthesis of antigenic SGL analogs aims at facilitating large scale production of 
immunogenic compounds, and allows to get rid of tedious lipid extraction from cultured M. 
tuberculosis strains. Immunisation studies with synthetic SGL analogs involving CD1b-
transgenic mice are ongoing, and preliminary data will be presented in the next chapter of this 
thesis. 
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CHAPTER 3 
 
 
Design of lipid-based subunit vaccines 
 
 Approximately one third of the world’s population is infected with the causative 
bacterial agent Mycobacterium tuberculosis, and roughly 10% of these individuals will 
develop active tuberculosis within their lifetime. Of these individuals, approximately 2 
millions per year do not survive [443]. Antimicrobial drugs are available, but treatment is 
costly, lasts a minimum of 6 months, and results in substantial hepatotoxicity. The most 
frequently recommended and effective combination is isoniazid, rifampicin, pyrazinamide, 
and ethambutol for 2 months, followed by isoniazid and rifampicin for 4 months [444]. In 
addition, the number of cases of multidrug-resistant tuberculosis (MDR-TB), i.e. resistant to 
rifampicin and isoniazid, and extensively resistant tuberculosis (XDR-TB), i.e. resistant to at 
least rifampicin and isoniazid, increases, multiplying the cost of treatment by a factor of 100 
or rendering it ineffective [445]. It is interesting to notice that isoniazid and pyrazinamide 
function by inhibiting mycolic acids biosynthesis. When the disease becomes active, 75% of 
the cases are pulmonary TB, with a large spectrum of symptoms including prolonged cough, 
bloody cough, fever and weight loss. In the other 25% of active cases, the infection moves 
from the lung to extrapulmonary infection sites including the central nervous system (CNS) 
and the lymphatic system, and may infect other organs in rare cases. Diagnosis rely on acid-
fast staining of sputum samples and skin testing with tuberculin (PPD), but new blood tests 
relying on IFNγ production by T cells in response to the presence of protein antigens from M. 
tuberculosis are on the way [446, 447]. BCG, an attenuated M. bovis strain, is widely 
administered worldwide as a vaccine against tuberculosis, but its efficacy remains 
controversial. BCG effectively protects infants from tuberculosis, but immunity declines with 
age and fails to protect adults against pulmonary tuberculosis, that is the primary source of 
dissemination [448-450]. In addition, BCG vaccination is ineffective for people that have 
been pre-sensitized to some species of environmental mycobacteria [451]. Therefore, a more 
effective vaccine against tuberculosis would be highly desirable. 
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It is important to mention that all successful vaccines developed thus far against acute 
diseases like smallpox, anthrax and rabies, function largely through production of specific 
antibodies. Design of vaccines against intracellular bacterial pathogens like M. tuberculosis 
remains more challenging since the pathogen hides within cells and thus escapes immune 
attack of antibodies. The novel vaccines against tuberculosis can be broadly divided into 
subunit vaccines, on one hand, and live attenuated vaccines, on the other. Subunit vaccines 
are made of one or two antigens, delivered with powerful adjuvants or by novel systems such 
as modified vaccinia virus Ankara, so the immune response during infection is directed 
against these antigens. Such antigens are selected on the basis of criteria such as strong 
recognition by the immune system during tuberculosis and high abundance or active 
secretion by M. tuberculosis during infection. It is the case for secreted mycobacterial 
antigens from the Ag85 complex, that might induce protective memory T lymphocytes when 
given as fusion proteins [452-454] or if expressed in a modified vaccinia virus Ankara [455]. 
This is based on the assumption that a protective immune response can be constituted by 
potent reactivity against a limited number of antigens. Concerning live attenuated vaccines, 
attempts have been made to genetically modify BCG, by inserting Ag85B [456] or by 
inserting listeriolysin to facilitate the escape of the bacilli from the phagosome into the 
cytoplasm [457], to improve its immunogenicity and thus vaccine efficacy. These vaccines 
are aimed at replacing BCG and must therefore be either safer or more effective than BCG. 
During infection of the lung, M. tuberculosis most likely enters alveolar macrophages and 
traffics to draining lymph nodes. The entry of M. tuberculosis into macrophages and DCs can 
occur via different receptor molecules including complement receptors, mannose receptor, 
DC-SIGN and Fc receptors [458-460], but also via uptake of apoptotic bodies and exosomes 
[217]. Upon internalization, mycobacterial phagosomes undergo maturation and fuse with 
lysosomes where the bacteria are degraded [461-467]. Resulting peptidic and lipidic 
fragments are then generated, enter respective presentation pathways and are loaded onto 
antigen-presenting molecules. In draining lymph nodes, macrophages and DCs present 
mycobacterial antigens to T cells which become activated and traffic back to the lung, where 
waves of infiltrating cells wall off infected macrophages present in structures called 
granulomas, resulting from the dynamic interaction between M. tuberculosis and the 
macrophages and T cells trying to kill them. Within these structures, and as long as the host 
immunity is effective, there’s usually no adverse effect of M. tuberculosis on the host’s 
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health [468]. This means that priming of T cells and rapid migration into the infected lungs 
are of critical importance in protection. The priming of specific T cells requires efficient 
presentation of mycobacterial antigens, and both M. tuberculosis and BCG are able to 
interfere with these processes to persist in the host. As described above, on entering 
macrophages, M. tuberculosis and BCG reside within phagosomes, which, under normal 
circumstances, undergo maturation, become acidified and fuse with lysosomes which contain 
hydrolases, lipases and peptidases that kill the bacillus. M. tuberculosis and BCG are able to 
arrest acidification of phagosome, enabling them to grow and persist within these vacuoles 
[222]. M. tuberculosis interferes with phagosome-lysosome fusion by preventing 
phosphatidylinositol 3-phosphate (PI3P) accumulation on phagosomal membranes [469]; by 
secreting the soluble kinase PknG inside the macrophage phagosomes that is further 
translocated into the host’s cytosol [470]; and by recruiting coronin 1 to phagosomes that 
leads to influx of calcium and activation of calcineurin [223]. Despite this, the host responds 
by cross-priming both CD8+ and CD4+ T cells via MHC class I and MHC class II 
presentation pathways, respectively [217, 471]. In addition, unconventional T cells, that are 
glycolipid-specific and CD1-restricted, are also stimulated during M. tuberculosis infection 
[152, 178, 217]. Immunity generated by BCG vaccination comprises a wide spectrum of T 
cell phenotypes stimulated by protein and lipid antigens. However, the capacity of M. 
tuberculosis to block their transfer to lysosomes is operational almost exclusively in 
nonactivated macrophages. Once macrophages have become activated, M. tuberculosis is 
rapidly transferred to lysosomes where they are destroyed by bactericidal activities such as 
the generation of reactive oxygen and nitrogen. Here should also be noticed that other 
mechanisms allowing M. tuberculosis survival include its ability to inhibit antigen processing 
and expression of MHC class II molecules on the surface of infected APCs via TLR2 [472, 
473], to induce T cell apoptosis [474-476], to neutralize the effect of nitric oxide generated 
within activated macrophages [477-479], to modulate macrophage activation via LAM-
related lipid species [480, 481], and to reduce cross-priming between infected and non-
infected cells by inhibiting apoptosis of infected cells [482, 483]. Recently, an additional 
evasion strategy that has been proposed consists of uncoupling the sequential relationship 
between MHC class II antigen loading and maturation of DCs, leading to evasion of peptide, 
but not lipid antigen presentation [484]. Here must also be noticed that both M. tuberculosis 
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and BCG interfere with the generation and function of APCs by reducing group 1 CD1 
expression and subsequent T cell responses [290, 291]. 
Studies in mice have demonstrated that a Th1 cytokine profile is required for control of 
infection, with Th2 cells having little or no protective capacity. Moreover, IFNγ and TNFα 
are key cytokines in that they activate macrophages to control bacterial proliferation by 
increasing phagosomal-lysosomal fusion [485, 486] and autophagy [487]. Macrophage 
activation can also occur via TLR signaling [488, 489], and regulation of phagosome 
maturation seems to occur through the TLR adaptor protein myeloid differentiation factor 88 
(MyD88) and the mitogen-associated protein kinase (MAPK) p38 protein [490, 491]. 
One key in optimizing vaccination strategies against tuberculosis may lie in improving access 
of antigen to presentation pathways, thus enabling highly efficient T cell priming to 
mycobacterial antigens. The lipids that we identified and generated, namely GroMM and 
SGL12, might constitute minimal structures to be loaded onto CD1b molecules via 
internalization without processing, thus facilitating efficient and specific T cell priming. 
Here, we further evaluated the potential use of these lipidic antigens in subunit vaccines, and 
propose some clues to enhance their immunogenic properties. 
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 Results 
 
GroMM immunogenicity is increased by lipidic adjuvants 
and structural modifications of its hydrophobic tail 
 
 During GroMM characterization (see Chapter 1), we noticed that GroMM-reactive T 
cells (Z5B71) were also responding to polar lipidic fractions isolated from M. bovis BCG that 
should not contain GroMM. Indeed, MALDI-Tof-MS analysis of these fractions did not 
reveal the presence of GroMM (not shown). However, they were enriched in PIMs, that do 
not stimulate Z5B71 T cells. These findings led us to the hypothesis that these immunogenic 
polar fractions may contain traces of GroMM in non-detectable quantities, whose antigenic 
properties may be enhanced by the presence of PIMs. Therefore, we tested mixtures of 
GroMM/PIM2 in T cell stimulation assays using DCs as APCs and the Z5B71 T cell clone 
(Figure 38). The presence of PIMs markedly increased GroMM stimulatory capacity, in a 
dose-dependent manner, whereas PIM2 alone did not elicit any T cell response. 
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Figure 38: Effect of PIM2 on GroMM stimulatory capacity. Human DCs were pre-incubated 
with different concentrations of GroMM/PIM2 before addition of T cells. The antigen 
concentration on the x axis corresponds to GroMM concentration, except for the negative 
control. IFNγ release was used to quantify T cell activation and is expressed as the mean 
pg/mL (± SD; n=3). The data are representative of three independent experiments. 
 
Maximal adjuvant effect was obtained with 50% PIM2. Both efficacy and potency of GroMM 
were increased. Comparable results were obtained with PIM6 (not shown). Other PI-related 
lipids, i.e. PI, LM and LAM, were also tested in mixture with GroMM and showed the same 
tendency whereas, alone, they did not elicit any response from GroMM-specific T cells 
(Figure 39A, 39B and 39C). 
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Figure 39: Effect of PI (A), LM (B) and LAM (C) on GroMM stimulatory capacity. Human 
DCs were pre-incubated with different concentrations of GroMM/adjuvant before addition of 
T cells. The antigen concentration on the x axis corresponds to GroMM concentration, except 
for the negative control. IFNγ release was used to quantify T cell activation and is expressed 
as the mean pg/mL. The data are representative of three independent experiments. 
 
It is interesting to notice that also non PI-related lipids are capable of enhancing GroMM 
stimulatory capacity. It is the case for Ac2SGL, that increases both efficacy and potency of 
GroMM, in a manner comparable to PI, PIMs, LM and LAM (Figure 40A). 
A B 
C 
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Figure 40: Effect of Ac2SGL (A) and DAT (B) on GroMM stimulatory capacity. Human 
DCs were pre-incubated with different concentrations of GroMM/adjuvant before addition of 
T cells. The antigen concentration on the x axis corresponds to GroMM concentration, except 
for the negative control. IFNγ release was used to quantify T cell activation and is expressed 
as the mean pg/mL. The data are representative of three independent experiments. 
 
Ac2SGL, PI, PIMs, LM and LAM are all negatively charged. To evaluate the putative effect 
of the charge, activation experiments were carried out using DAT, that possess a structure 
similar to Ac2SGL but are not sulfated, therefore bearing no negative charges. These 
compounds still have an enhancing effect when mixed with GroMM, but markedly reduced 
as compared to Ac2SGL (Figure 40B). 
It is interesting to notice that also chemical modifications of the structure of the hydrophobic 
tail of GroMM might influence GroMM immunogenicity, as reduction of a ketonic group to 
an alcohol at position 41 of the meromycolic chain strongly increases specific T cell pro-
inflammatory response (Figure 41). One possible explanation is that this reduction may 
modify positioning of the glycerol head and subsequent recognition by the TCR by 
interfering with the way the end of the meromycolic chain protrudes out of the F’ channel. 
A B 
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Figure 41: Effect of chemical structural modification of the lipid tail on GroMM stimulatory 
capacity. Human DCs were pre-incubated with different concentrations of GroMM or 
reduced GroMM before addition of T cells. IFNγ release was used to quantify T cell 
activation and is expressed as the mean pg/mL. The data are representative of three 
independent experiments. 
 
These data show that other lipids may enhance GroMM immunogenicity, and that this effect 
might be related to their negative charges. In addition, structural modifications of the 
hydrophobic tail also seem to influence the immunogenic properties of GroMM. 
 
  PIMs and GroMM do not increase Ac2SGL immunogenicity 
 
 In a second series of experiments, we tried to determine whether polar or apolar lipids 
could increase Ac2SGL immunogenicity, as SGLs are promising compounds to be used in 
vaccines. Therefore, we tested mixtures of Ac2SGL/PIM2 and Ac2SGL/GroMM in T cell 
stimulation assays using DCs as APCs and the Z4B27 Ac2SGL-specific T cells as responder 
cells (Figure 42). In this case, the presence of PIMs did not influence Ac2SGL antigenic 
properties. The decrease of activity of the mixtures was even proportional to the decrease of 
Ac2SGL present in the sample (Figure 42). 
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Figure 42: Effect of PIM2 on Ac2SGL stimulatory capacity. Human DCs were pre-incubated 
with different concentrations of Ac2SGL/PIM2 before addition of T cells. The concentration 
on the x axis corresponds to the complete mixture concentration. IFNγ release was used to 
quantify T cell activation and is expressed as the mean pg/mL. The data are representative of 
three independent experiments. 
Mixture (µg/mL) 
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Use of GroMM to increase Ac2SGL stimulatory capacity failed as well (Figure 43). 
 
 
 
Figure 43: Effect of GroMM on Ac2SGL stimulatory capacity. Human DCs were pre-
incubated with different concentrations of Ac2SGL/GroMM before addition of T cells. The 
antigen concentration on the x axis corresponds to Ac2SGL concentration, except for the 
negative control. IFNγ release was used to quantify T cell activation and is expressed as the 
mean pg/mL. The data are representative of three independent experiments. 
 
These data show that neither PIMs (polar) nor GroMM (apolar) lipids enhance Ac2SGL 
antigenicity. 
 
Lipid binding proteins can be used to increase 
Ac2SGL immunogenicity 
 
 Lipid binding proteins (LBPs) are proteins ubiquitously distributed inside the cell, and 
also present in the extracellular milieu. Some have been shown to be involved in lipid 
loading/unloading onto CD1 molecules, pointing out crucial roles for LBPs in lipid 
immunogenicity. Precise function remains unclear for most of them, but several studies have 
shown their involvement in lipid solubilization and trafficking to acceptor membranes. Sterol 
carrier protein-2 (SCP-2) and human tocopherol associated protein (hTAP) have been shown 
to bind a wide variety of lipids [492-498], and shuttle them between membranes [492, 499-
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506]. For these reasons, they were tested for their ability to increase stimulatory capacities of 
SGLs. When used in mixture with Ac2SGL in activation assays, SCP-2 showed a striking 
ability to facilitate T cell response (Figure 44A), especially in the first hours of antigen 
uptake and presentation by DCs (Figure 44B). 
 
A 
 
B 
 
 
Figure 44: SCP-2 increases Ac2SGL stimulatory capacity. (A) Human DCs were pre-
incubated with different concentrations of Ac2SGL in the presence or absence of SCP-2 
before addition of T cells. (B) Human DCs were pulsed with SGL12 in the presence or 
absence of SCP-2 for different amounts of time, and washed before addition of T cells. IFNγ 
release was used to quantify T cell activation and is expressed as the mean pg/mL. The data 
are representative of three independent experiments. 
 
Similar results were obtained with hTAP (Figure 45), clearly indicating that LBPs have the 
ability to increase the stimulatory capacity of polar lipid antigens, probably by allowing 
better solubilization, thus facilitating uptake by APCs and increasing availability for 
presentation to T cells. 
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Figure 45: hTAP increases Ac2SGL stimulatory capacity. Human DCs were pulsed with 
SGL12 in the presence or absence of hTAP for different amounts of time, then washed before 
addition of T cells. IFNγ release was used to quantify T cell activation and is expressed as the 
mean pg/mL. The data are representative of three independent experiments. 
 
DCs from CD1b-trangenic mice present SGLs to Ac2SGL-specific 
T cells in a CD1b-restricted manner 
 
 To further carry out preclinical studies involving SGLs, we generated transgenic mice 
expressing CD1b antigen-presenting molecule. CD1b functionality was assessed by 
activation assays using DCs from CD1b-transgenic mice as APCs to stimulate CD1b-
restricted Ac2SGL-specific human T cells (Figure 46). CD1b-transgenic DCs were able to 
elicit a strong T cell response by presenting synthetic SGL12 analog (Table I), whereas DCs 
from wild-type (WT) mice did not activate T cells (Figure 46). CD1b-restriction was further 
confirmed by inhibition with mAbs (Figure 47). 
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Figure 46: DCs from CD1b-transgenic mice successfully present SGLs to Ac2SGL-specific 
human T cells. GM-CSF release was used to quantify T cell activation and is expressed as the 
mean pg/mL (± SD; n=3). The data are representative of three independent experiments. 
 
 
 
 
Figure 47: Presentation of SGLs using DCs from CD1b-transgenic mice to Ac2SGL-specific 
T cells is CD1b-restricted. Mouse DCs were incubated with or without SGL12 and mAbs 
before addition of T cells. GM-CSF release was used to quantify T cell activation and is 
expressed as the mean pg/mL (± SD; n=3). The data are representative of three independent 
experiments. 
 
We concluded that the CD1b molecule expressed by CD1b-transgenic mice is fully 
functional, and that these mice are suitable for pre-clinical purposes. 
 116 
Generation of shCD1b:SGL12 dimers to stain  
CD1b-retricted Ac2SGL-specific T cells 
 
 The current lack of molecular tools to stain CD1b-restricted T cells is a major 
limitation to the study of antigens presented by CD1b molecules. Therefore, we generated 
shCD1b:SGL12 complexes and used them to stain CD1b-restricted Ac2SGL-specific T cells. 
First, we produced and purified recombinant shCD1b as decribed before [133]. Second, 
shCD1b molecules were mixed with a mAb directed against the BirA tag of shCD1b, and 
loaded with SGL12. Plate-bound activation assays using these complexes confirmed their 
ability to stimulate only CD1b-restricted Ac2SCL-specific T cells (Figure 48A). Then, we 
used these dimers for flow cytometry analyses, and they successfully stained the TCR of 
Z4B27 cells (Figure 48B). 
 
A                                                                       B 
                 
 
Figure 48: (A) shCD1b:SGL12 complexes exclusively stimulate CD1b-restricted Ac2SGL-
specific T cells (Z4B27), as γδ T cells (G2B2) and CD1d-restricted cells (JS63) do not 
respond. Complexes were coated on 96 well plates before addition of T cells. GM-CSF 
release was used to quantify T cell activation and is expressed as the mean ng/mL (± SD; 
n=3). The data are representative of three independent experiments. (B) Human Ac2SGL-
specific T cell clone stained by shCD1b:SGL12 dimers. Numbers on the x axis correspond to 
the median fluorescence intensity. Numbers on the y axis corresponds to the number of 
events/cells acquired. 
shCD1b:empty shCD1b:SGL12 
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Immunization of CD1b-transgenic mice with synthetic SGLs leads 
to priming and expansion of SGL-specific T cells 
 
 Next, the potential of synthetic SGLs to prime T cells in vivo was tested. CD1b-
transgenic mice were immunized with SGL12. To detect SGL-specific T cells by flow 
cytometry, we used shCD1b:SGL12 dimers. After immunization, phenotypic analysis of cells 
from lymph nodes confirmed the presence of shCD1b:SGL12-positive CD4+ and 
shCD1b:SGL12-positive CD8+ T cells in CD1b-transgenic mice (Figure 49). 
 
 A        B          C 
 
 
Figure 49: Immunization of CD1b-transgenic mice with SGL12 leads to priming and 
expansion of both CD4+ and CD8+ SGL12-specific T cells. (A) T cells were stained using 
unloaded CD1b dimers. (B and C) T cells were stained using CD1b dimers loaded with 
SGL12. Dead cells, B cells and macrophages were gated out. Numbers on the x and y axis 
correspond to the median fluorescence intensities. 
 
These data suggest that immunization with SGL12 leads to consequent priming and 
expansion of SGL-specific T cells, thus confirming the potential of SGLs to be used in 
subunit vaccines. 
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 Discussion 
 
 GroMM and diacylated sulfoglycolipids are CD1b-restricted antigens that have been 
identified as potential candidates for the design of lipid-based vaccines [178] [This thesis]. 
In order to increase their immunogenicity, we tried different approaches to facilitate their 
solubilization, thus enhancing their availability for APC uptake and presentation to T cells. In 
the case of GroMM, that is quite apolar, we found that mixtures with polar compounds like 
PI-related species remarkably increased both its potency and efficacy. One explanation to this 
phenomenon could be related to the charge of the polar lipids, as compounds like DAT, that 
bears no negative charges, showed only a minor effect on GroMM stimulatory capacity. This 
approach presents another considerable advantage due to the fact that antigenic bacterial 
lipids used to solubilize GroMM are also immunogenic, and might thus act in combination 
with GroMM to confer further protection in subunit vaccines. It is also interesting to notice 
that chemical modifications of GroMM structure enhances its stimulatory capacity as well, 
indicating that analogues with stronger antigenicity can be synthesized. 
In the case of Ac2SGLs, attempts to increase solubilization using both polar and apolar 
compounds failed. We speculated that lipid binding proteins capable of binding a large panel 
of lipid ligands might be able to behave as “solubilizers” too. Indeed, proteins like SCP-2 and 
hTAP have been shown to be able to transfer lipids to enzymes or between membranes [492, 
499-506]. The results presented here confirm their capability to enhance the stimulatory 
capacity of polar lipid antigens, especially in the first hours of antigen uptake and 
presentation by professional APCs. These LBPs might allow better solubilization of lipid 
antigens, thus facilitating lipid uptake by APCs and increasing lipid availability for 
presentation to T cells. For both SCP-2 and hTAP, we also noticed a tendency to interfere 
with T cell activation after long incubation with APCs (24 hrs). This phenomenon might be 
toxicity due to high amounts of the LBPs in the culture medium, and should be avoided by 
tuning the concentration of the LBPs. Even if the safety and effectiveness of such approaches 
has still to be tested in vivo, they provide new hints to optimize the immunogenicity of lipid 
antigens. 
One major limitation to the study of antigens presented by CD1b molecules is the current 
lack of molecular tools to stain CD1b-restricted T cells. Therefore, we generated 
shCD1b:SGL12 dimers, that specifically stimulated CD1b-retricted Ac2SGL-specific T cells 
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in plate-bound activation assays. These dimers were also able to stain the TCR of Z4B27 
cells, and can be used for flow cytometry analyses. The field of application of such dimers is 
wide, and they may allow study of CD1b-restricted SGL-specific T cell priming and 
expansion upon immunization, but also how these T cells behave in diseases. Successful 
loading of lipid ligands other than SGLs in these complexes may allow precise study of 
CD1b-restricted T cells. 
Another limitation to the establishment of vaccines relying on lipids presented by CD1b 
molecules was the absence of a suitable animal model easy to handle. Mice do not express 
group 1 CD1 molecules, preventing any in vivo experimentation in these animals. Therefore, 
CD1b-trangenic mice were generated in our laboratory, and the functionality of the CD1b 
molecule expressed on the surface of APCs is shown here. We started to carry out 
immunization studies with our most stimulatory SGL analog, and our data using 
shCD1b:SGL12 dimers confirm priming and expansion of specific T cells in vivo. These 
findings are very encouraging, as we found that human Ac2SGL-specific T cells kill 
intracellular M. tuberculosis [178]. It seems that also CD4+ T cells are expanded after 
immunization with SGL12. It is not known whether this type of cells directly contributes to 
cytotoxic and antimicrobial response in our case, but recent findings do not exclude such 
possibility [507]. Further characterization of these T cells is ongoing. 
Overall, the data described in this last chapter confirm that lipid antigens presented by group 
1 CD1 molecules can successfully prime and expand lipid-specific T cells in vivo. In 
addition, they prove that potent stimulatory analogs can be chemically produced and provide 
some clues about the way to optimize their properties using other antigenic or non antigenic 
compounds. The advantage of a vaccine that would kill bacteria instead of simply controlling 
their pathogenicity mostly relies on the cost of the treatment, as antibiotics are hardly 
affordable for low-income countries. In addition, it might prevent further development of 
resistant strains. Use of lipid antigens rather than peptides might also limits immune escape 
due to mutations, as lipids are products of multi-step synthesis. In the case of GroMM- and 
Ac2SGL-based vaccination, another important point is their potential to be used as pre- and 
post-exposure vaccines. Indeed, because they are important constituents of the mycobacterial 
cell wall, they might be present in the structure of both active and dormant M. tuberculosis, 
that may not be the case for peptidic antigens. 
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Further studies, conducted in vivo in our CD1b-transgenic mice will evaluate safety and 
protective effect of lipid vaccination upon infection. 
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CONCLUSIONS 
 
 
 The work presented in this thesis aimed to identify and evaluate natural and synthetic 
lipid antigens as potential candidates to be included in subunit anti-mycobacterial vaccines. 
Indeed, lipid-based vaccines have already been shown to provide protection against M. 
tuberculosis [293]. 
 Identification of GroMM as a lipid antigen widely distributed among bacteria 
belonging to the Corynebacteria-Mycobacteria-Nocardia group required use of a whole panel 
of techniques, from lipid extraction and fractionation, to in vitro assays using human cells 
and blood samples from patients. The fact that PPD+ patients, developing active tuberculosis, 
lack GroMM-reactive T cells is of primary interest. Whether their priming prevents re-
activation of dormant M. tuberculosis needs to be carefully assessed. 
 Ac2SGLs are immunogenic lipids found in the external part of the mycobacterial cell 
wall and are typical of virulent mycobacteria [178, 508, 509]. Combined analysis of binding 
and stimulatory capacity of synthetic SGL analogs allowed us to define structural features 
that permit fine tuning of their antigenicity. These features might help in the design of 
chemical compounds produced in large-scale for vaccinal purposes. Structural variations 
around the same antigenic moiety have the potential to precisely induce the required specific-
T cell response, possibly avoiding side-effects, anergy, or auto-immune drifts. 
 Another interesting finding is the fact that different antigenic lipids have the ability to 
enhance their respective stimulatory capacity when mixed together. This means that a 
combination of lipids injected together during immunization may stimulate a whole panel of 
T cells differing in their specificity in a stronger manner compared to the same lipid species 
alone. In addition, the presence of recombinant LBPs seems to facilitate lipid uptake by 
professional APCs and subsequent presentation to T cells. 
 For the first time, CD1b dimers were generated and proven successful in the staining 
of CD1b-retricted T cells. Such molecular tool should greatly help to study these T cells, that 
are of primary importance in the immune response to mycobacteria. 
 Here are also shown for the first time data using a suitable mouse model to study 
lipid-based immunization. CD1b-transgenic mice immunized with synthetic SGL do show 
priming and expansion of SGL-specific T cells, confirming that pure lipids are immunogenic 
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in vivo. Analysis of these mice after M. tuberculosis infection will definitely shed light on the 
protective effect of SGL-related compounds. 
 Peptide-based subunit vaccines aim at improving protection by being administered 
after BCG vaccination, and already showed convincing effect in animal models [510-513]. 
However, without previous BCG vaccination, peptide-based mixtures might fail to stimulate 
lipid-reactive T cells required for protection. Thus, new vaccination strategies can easily be 
imagined, e.g. vaccination with BCG in combination with defined lipid/protein mixtures, or 
with defined lipid/protein mixtures without BCG, followed by a lipid/protein boost. In 
addition, lipid-based subunit vaccines might be used as pre- and post-exposure vaccines, 
allowing precise targeting of T cell populations that need to be re-stimulated after infection. 
Recently, the Global Advisory Committee on Vaccine Safety established by the World 
Health Organization recommended that BCG should not be administered to children known 
to be HIV infected for matter of safety [514]. This could present a major obstacle to novel 
vaccine approaches for vaccines relying on BCG prime. Prime vaccination relying on defined 
lipid species may represent an alternative. 
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MATERIALS AND METHODS 
 
 Synthesis of analogs, Mass Spectrometry and NMR were done by collaborators 
 
Reagents. (R)-isopropylidene-glycerol and (S)-isopropylidene-glycerol, glyceryl 
tripalmitate (tripalmitin), 1,2 dipalmitoyl-sn-glycerol ((S)-glycerol 1,2-dipalmitate) and 
monopalmitoyl glycerol (1-O-palmityl-rac-glycerol) were purchased from Sigma (Saint 
Quentin Fallavier, France). 
 
Bacterial Strain and Culture Conditions. Nocardia asteroides and 
Corynebacterium glutamicum were grown in suspension during 2 to 3 days at 32°C on Luria 
Broth and Brain Heart Infusion medium, respectively. Mycobacteria were grown during 4 to 
8 weeks at 37°C on Sauton's medium as surface biofilm. Cells were harvested, separated 
from the culture media, and left in chloroform/methanol (2:1, v/v) at room temperature to kill 
bacteria. 
 
Cell Culture. Human promyelocytic THP-1 cells were transfected with cDNA of 
human CD1A, or CD1B, or CD1C genes or double-transfected with CD1B and CD1E using 
the BCMGS-Neo and -Hygro vectors by electroporation. Cells were grown in RPMI-1640 
supplemented with 10% fetal calf serum (FCS), 10 mM HEPES, 2 mM UltraGlutamine II, 
MEM nonessential amino acids, 1 mM Na-pyruvate and 100 µg/mL kanamycin (all from 
Invitrogen, Basel, Switzerland). DCs were isolated from peripheral blood mononuclear cells 
(PBMCs) of healthy donors by culturing in the presence of recombinant IL-4 and GM-CSF, 
as described previously [13]. T cell clones were generated as described [515], and grown in 
RPMI-1640 supplemented with 5% AB human serum (Swiss Red Cross), 10 mM HEPES, 2 
mM UltraGlutamine II, MEM nonessential amino acids, 1 mM Na-pyruvate, 100 µg/mL 
kanamycin and 100 units/mL human recombinant IL-2. In Chapter 3: mouse DCs were 
derived from bone marrow after 8 days differenciation in RPMI-1640 supplemented with 
10% fetal calf serum (FCS), 10 mM HEPES, 2 mM UltraGlutamine II, MEM nonessential 
amino acids, 1 mM Na-pyruvate, 100 µg/mL kanamycin (Invitrogen) and 10 µg/mL mouse 
GM-CSF. 
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T Cell Activation Assays. In Chapter 1 and Chapter 3: DCs (3x104/well) or CD1-
transfected THP-1 cells (3x104/well) were incubated for 2 hr at 37°C with different 
concentrations of sonicated antigens before the addition of T cells (105/well in triplicate). 
Supernatants were harvested after 36 hr of incubation, and cytokine release was measured by 
using enzyme-linked immunosorbent assay (ELISA) kits (IFNγ from Instrumentation 
Laboratory, Schlieren, Switzerland; TNFα from BD Pharmingen, Basel, Switzerland). Data 
are expressed as mean pg/mL or ng/mL ± standard deviation (SD) of triplicates. In Chapter 2 
and Chapter 3: The Ac2SGL-specific and CD1b-restricted Z4B27 T cell clone has been 
characterized previously [178]. T cell activation assays with human DCs as APCs were 
performed as previously described [178]. Briefly, DCs (3 x 104/well) in RPMI-1640 medium 
containing 10% FCS (Invitrogen, Switzerland) were preincubated for 2 hr at 37°C with 
different concentrations of sonicated Ac2SGL or synthetic SGL analogs before the addition of 
T cells (105/well in triplicate). Supernatants were harvested after 18 hr of incubation, and 
GM-CSF release was measured by using enzyme-linked immunosorbent assay (ELISA) 
(R&D, Europe). Data are expressed as mean ng/mL ± SD of triplicates. 
For the plate-bound activation assays, 128 nM of each shCD1b:Ac2SGL or shCD1b:SGL 
complex were coated on Nunc MaxisorpTM flat-bottom 96 well plate (NUNC, Roskilde, 
Denmark) for 16 hr at 4°C. Plates were then washed before addition of T cells (105/well in 
triplicate) in RPMI-1640 medium containing 10% FCS. Supernatants were collected after 18 
hr of incubation, and GM-CSF release was measured by ELISA (R&D, Europe). Data are 
expressed as mean ng/mL ± SD of triplicates. In Chapter 3: For classical T cell activation 
assays, SCP-2 was used at 25 µg/mL, after overnight incubation at 56°C with or without 
treatment with 50 µg/mL proteinase K. For kinetic experiments using LBPs, human DCs 
were incubated for different amounts of time with 3 µg/mL of SGL12, in presence or absence 
of 4 µg/mL of LBP before washing and incubation with T cells. 
 
Analysis of CD1 Restriction. CD1 restriction was investigated by evaluating the 
inhibition of the T cell response in the presence of the following mAb supplemented at 10 
µg/mL 30 min before the addition of T cells: In Chapter 1: OKT6 (anti-CD1a, American 
Type Culture Collection ATCC CRL-8019), WM-25 (anti-CD1b; Immunokontakt, Lugano, 
Switzerland), L161 (anti-CD1c; Instrumentation Laboratory), W6-32 (anti-MHC class I, 
ATCC) and L243 (anti-MHC class II, ATCC). Anti-TCRVγ9 (B3) mAb was used as 
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irrelevant mAb. In Chapter 3: M5-114 (anti-mouse MHC class II), 15F7 (anti-mouse CD1d, 
ATCC HB322) and BCD1b3.1 (anti-CD1b). 
 
Pulsing and infection of DCs with M. tuberculosis. M. tuberculosis was killed at 
80°C for 20 min and incubated in RPMI-1640 medium containing 10% FCS for 2 hr at 37°C 
with DCs (3x104/well) before addition of T cells (105/well in triplicate). DCs were infected as 
previously described [175] and IFNγ release was monitored by ELISA. 
 
Lipidic Fractions Used for Generation of T Cell Clone. The Z5B71 T cell clone 
was generated as described [178] by stimulating PBMCs of a PPD+ healthy donor with a M. 
bovis BCG PIM2-enriched fraction [516]. Briefly, M. bovis BCG cells were suspended in 
chloroform/methanol (1:1, v/v) and filtered four times. The chloroform/methanol extract was 
concentrated and constituted the lipidic fraction, which was further partitioned between water 
and chloroform. The chloroform phase was evaporated and suspended in a minimum volume 
of chloroform. The addition of acetone overnight at 4°C led to formation of a precipitate, 
which was centrifuged (3,000 g at 4°C for 15 min) to generate an “acetone-soluble” phase 
and an “acetone-insoluble” phase. The “acetone-soluble” phase was applied to a QMA-
Spherosil M (BioSepra SA, Villeneuve-la-Garonne, France) column eluted successively with 
chloroform, chloroform/methanol (1:1, v/v), methanol to elute neutral compounds and then 
with chloroform/methanol (1:2, v/v) containing 0.1 M ammonium acetate to elute negatively 
charged compounds. This last fraction corresponds to the “PIM2-enriched fraction”. 
 
Lipidic fractions from several actinomycetes. Different lipidic fractions were 
prepared (as described above) from several actinomycetes species and tested against the 
Z5B71 T cell clone. The lipidic fractions from the following bacteria were tested: M. 
smegmatis, M. tuberculosis H37Ra, M. fortuitum, M. xenopi, N. asteroides and C. 
glutamicum, the “acetone-soluble” phase from M. smegmatis, M. tuberculosis H37Rv, M. 
gastri, M. kansasii, M. marinum and M. bovis BCG. The “acetone-insoluble” lipids from M. 
tuberculosis H37Rv, M. gastri, M. kansasii, M. marinum and M. bovis BCG were also tested. 
 
Purification of the GroMM from M. bovis BCG. The "acetone-insoluble" fraction 
from M. bovis BCG, obtained as described above, was subjected to methanol precipitation 
 126 
giving “methanol soluble” and “methanol insoluble” fractions. The “methanol-insoluble” 
fraction (150 mg) was fractionated on a silica acid column (1.3 x 23 cm) eluted with 7x175 
mL of chloroform (fractions 1-7), 8x200 mL of chloroform/methanol (95:5, v/v) (fractions 8-
15), 9x225 mL of chloroform/methanol (9:1, v/v) (fractions 16-24), 7x175 mL of 
chloroform/methanol (85:15, v/v) (fractions 25-31) and 7x175 mL of chloroform/methanol 
(7:3, v/v) (fractions 32-38). Fractions 5 to 8 were found to contain GroMM and were pooled. 
Purifications were checked by TLC on aluminium-backed silica gel plates (Alugram Sil G; 
Macherey-Nagel) using as migration solvent chloroform/methanol (95:5, v/v). Anthrone 
(9,10-dihydro-9-oxo-anthracene) (Sigma) at 0.2% dissolved in H2SO4 at 85% was used to 
detect glycolipids. 
 
GroMM Acetylation. Peracetylation was performed on 200 µg of GroMM which 
were dissolved in acetic anhydride/anhydrous pyridine (1:1, v/v) and heated at 80°C for 30 
min. The reaction mixture was dried under a stream of nitrogen and dissolved in chloroform 
for MALDI-Tof-MS analysis. For selective acetylation of GroMM hydroxyl functions, 16 µL 
of acetic acid were added to 10 mg of GroMM dissolved in 150 µL of pyridine and kept 3 hr 
at 0°C. Mono- and di-acetylated GroMM were extracted by CHCl3 and purified on silica 
column eluted successively by CHCl3 and CHCl3/CH3OH 95/5 (v/v). The number of acetyl 
substituents and their location on GroMM were determined by MALDI-Tof-MS and NMR 
analysis. 
 
GroMM Saponification. 800 µL of methoxyethanol/KOH 20% (7:1, v/v) were added 
to 500 µg of GroMM. The mixture was then heated at 100°C for 3 h. After cooling and 
acidification by aqueous sulphuric acid at pH 3.0, mycolic acids were extracted three times 
by diethyl ether (v/v). Ether phases were pooled, washed five times with water and dried 
under a stream of nitrogen. Mycolic acids were redissolved in 100 µL chloroform for 
MALDI-Tof-MS analysis. 
 
GroMM Synthesis. Reactions were performed under argon in anhydrous solvents. 
(S)-1-O-(4-Methylbenzene sulfonyl)-2,3-O,O-isopropylidene-glycerol [425]: p-toluene 
sulfonyl chloride (0.3 g, 1.57 mmol) was added at 0°C to (R)-isopropylidene-glycerol (230 
mg, 1.74 mmol) dissolved in anhydrous pyridine (0.8 mL). After 24 hr at room temperature, 
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diethyl ether was added to the reaction mixture and the organic phase was washed 
sequentially with cold, 1 M hydrochloric acid, water, saturated sodium bicarbonate solution 
and water. The ether extract was dried on magnesium sulphate and concentrated. 
Chromatography on silica gel (elution with petroleum ether / ethyl acetate 4/1, v/v) gave the 
product (around 100 mg, 0.35 mmol). In the same manner, (R)-1-O-(4 methylbenzene 
sulfonyl)-2,3-O,O-isopropylidene-glycerol was obtained from (S)- isopropylidene-glycerol. 
Potassium mycolates: Mycolic acids (gift of Dr. M.A. Lanéelle, IPBS, Toulouse) were 
released from M. tuberculosis H37Rv cells as described [420]. Potassium mycolates were 
obtained by two successive washings of mycolic acids dissolved in chloroform with 10 mM 
hydrochloric acid and 5 M potassium hydroxide. After extraction with chloroform, potassium 
mycolates were dried on magnesium sulphate and concentrated. 
(S)-1-O-Mycoloyl-2,3-O,O-isopropylidene-glycerol [426]: Potassium mycolates (8 mg, ~6 
µmol) were added to (S)-1-O-(4-methylbenzenesulfonyl)-2,3-O,O-isopropylidene-glycerol (2 
mg, 7 µmol) in anhydrous dimethylformamide (0.150 mL) and stirred for 3 days at 135 °C. 
The reaction mixture was acidified by 1 M hydrochloric acid and extracted by diethyl ether. 
Ether extract was then washed with water, dried on magnesium sulphate and concentrated. 
Chromatography on silica gel (elution with petroleum ether / diethyl ether 5/1, v/v) gave the 
product (around 4 mg, 2.9 µmol). In the same way, (R)-1-O-mycoloyl-2,3-O,O-
isopropylidene-glycerol was obtained from (R)-1-O-(4 methylbenzene sulfonyl)-2,3-O,O-
isopropylidene-glycerol. 
(S)-1-O-Mycoloyl-glycerol (GroMM) [425]: 100 µL of concentrated hydrochloric acid 
(d=1.017) were added to (S)-1-O-Mycoloyl-2,3-O,O-isopropylidene-glycerol (4 mg, 2.9 
µmol) dissolved in diethyl ether (0.1 mL). After 10 min of stirring at room temperature, water 
was added to the reaction mixture and the product (3 mg, 2.3 µmol) was extracted with 
diethyl ether. The ether extract was dried on magnesium sulphate and concentrated. 
Supplemental purification was not necessary. (R)-1-O-mycoloyl-glycerol was also obtained 
using (R)-1-O-mycoloyl-2,3-O,O-isopropylidene-glycerol. 
 
MALDI-Tof-MS. In Chapter 1: MALDI-Tof-MS analysis were performed on a 4700 
Proteomics Analyser (with Tof-Tof Optics, Applied Biosystems) using the reflectron mode. 
Ionization was effected by irradiation with pulsed UV light (355 nm) from an Nd:YAG laser. 
GroMM samples were analyzed by the instrument operating at 20 kV in the positive ion 
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mode using an extraction delay time set at 20 ns. Typically, spectra from 100 to 250 laser 
shots were summed to obtain the final spectrum. The HABA (2-[4-hydroxy-phenylazo]-
benzoic acid) matrix (Sigma-Aldrich) was used at a concentration of ~10 mg/mL in 
ethanol/water (1:1, v/v). Then, 0.5 µL sample solution and 0.5 µL of the matrix solution were 
deposited on the target, mixed with a micropipette and dried under a gentle stream of warm 
air. The measurements were externally calibrated at two points with mycobacterial PIM. In 
Chapter 2: Analysis by MALDI-Tof-MS was performed on a Voyager DE-STR (PerSeptive 
Biosystems) using the reflectron mode. Ionization was effected by irradiation with pulsed UV 
light (337 nm) from an N2 laser. SGL samples were analyzed by the instrument operating at 
20 kV in the negative ion mode using an extraction delay time set at 200 ns. Typically, 
spectra from 2500 laser shots were summed to obtain the final spectrum. All of the samples 
were prepared for MALDI analysis using the on-probe sample cleanup procedure with cation 
exchange resin. The HABA matrix (2-[4-hydroxyphenylazo]-benzoic acid; Sigma-Aldrich) 
was used at a concentration of ~10 mg/mL in ethanol/water (1/1, vol/vol). Typically, 0.5 µL 
of SGL sample (10 µg) in a CHCl3/CH3OH (4/1) solution and 0.5 µL of the matrix solution, 
containing ~5-10 cation exchange beads, were deposited on the target, mixed with a 
micropipette, and dried under a gentle stream of warm air. The measurements were externally 
calibrated at two points with mycobacterial PIM. 
 
NMR Analysis. In Chapter 1: NMR spectra were recorded with an Avance DMX500 
spectrometer (Bruker) equipped with an Origin 200 SGI using Xwinnmx 2.6. GroMM was 
dissolved in CDCl3-CD3OD, (9:1, v/v) and analyzed in 200 x 5 mm 535-PP NMR tubes at 
298 K. Proton chemical shifts are expressed in parts per million downfield from the signal of 
the chloroform (δH/TMS 7.27). All the details concerning correlation spectroscopy and 
homonuclear Hartmann-Hahn spectroscopy sequences used and experimental procedures 
were as previously described [517]. In Chapter 2: 1H and 13C NMR spectra were recorded on 
Brucker ARX250, AV300 and DMX500 spectrometers, working at 250, 300 and 500 MHz 
respectively for the 1H and at 63, 75 and 126 MHz for the 13C. 
 
Recognition of GroMM by Lymphocytes from Tuberculosis Patients and 
Healthy Donors. PBMCs were purified from blood of healthy donors and tuberculosis 
patients after informed consent was given. All patients included in this study suffered from 
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culture proven pulmonary tuberculosis and were undergoing treatment with anti-tuberculosis 
drugs for 2 to 8 weeks at the time of blood donation. PBMCs (105/well) were cultured with 
autologous DCs (2x104/well) in the presence or absence of 10 µg/mL natural GroMM, PIM2 
or DAT. After 6 days supernatants were collected and tested for the presence of IFNγ by 
sandwich ELISA. PBMCs were kept at 37°C in supplemented RPMI 1640 medium (see 
above) during the 2 days of autologous monocytes differentiation to DCs. In parallel PBMCs 
were stimulated with 10 µg/mL PPD (Chiron) and recombinant ESAT6 (Lionex). Healthy 
donors that responded by releasing at least 250 pg/mL IFNγ in response to PPD were scored 
as BCG immunized. Donors that responded to both antigens were considered as latently M. 
tuberculosis infected. Those that did not respond to PPD were scored as PPD-negative. For 
individual experiments, a cocktail of CD1b- and CD1c-blocking antibodies (BCD1b3.1 and 
F10 at 10 µg/mL each) was added 30 min prior to GroMM to block CD1 presentation. 
 
Molecular Modeling. CD1b in complex with GroMM was obtained from GlcMM by 
replacing the glucose moiety in the glycolipid head of the molecule by glycerol. The starting 
point for this work was the crystal structure of the CD1b-GlcMM complex [432]. We have 
used the Builder and Biopolymer modules of InsightII (BIOSYM/MSI, San Diego) to replace 
the glucose moiety by glycerol. The bonds and partial charges have been corrected and 
adjusted to the CVFF force field. In order to position the new fragment optimally with 
respect to the neighboring residues, we minimized the energy of the molecule with the 
Discover module, following the standard simulated annealing (SA) protocol. During the 
procedure, only the glycerol atoms were allowed to move, along with the side chains of 
Phe75 and Arg79, the closest spatial neighbors. Molecular dynamics was simulated during 20 
ps with the time step of 1 fs, with temperature initially raised to 1000K and gradually lowered 
to 300K. The minimization was performed with the Conjugate Gradient algorithm, and was 
terminated upon reaching the threshold value for the root mean square gradients of 0.001 
kcal/mol. In order to be able to compare the results directly with the original complex, we 
have subjected the CD1b-GlcMM complex to the identical procedure. 
 
 Synthesis of sulfoglycolipids. Details of the preparation of all synthetic 
sulfoglycolipids and their physicochemical data will be described in a separate manuscript. 
Briefly, the synthesis of SGL analogs is based on a 7-reaction sequence with an overall 
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product yield of about 5%. Preparation of SGL analogs started from known 4,6,4’,6’-
benzylidene protected trehalose derivative 1 [518] which was selectively acylated on the 2 
position using palmitoyl chloride (or any other acid chloride) in pyridine. Use of a bidentate 
reagent (1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane TCl2) allowed the selective protection 
of the 2’ and 3’ positions of 2 in one step [519] and gave alcohol 3. This reagent was selected 
owing to its easy deprotection in the presence of the benzylidene groups. This approach 
leaves the hydroxyl on position 3 as the only potential acylation site for esterification of 
compound 3 by the second fatty acid. Unmasking of the 2’ and 3’ positions of 4 afforded diol 
5 which was selectively sulfated on the 2’ position [520]. The synthesis of SGLs was 
completed after removal of the benzylidene protecting groups under carefully controlled 
acidic conditions. Compound structures were analysed by 1H and 13C NMR at each step of 
the synthesis and final SGLs structures were confirmed by MALDI-Tof-MS analysis. 
 
 Preparation of M. tuberculosis multimethyl fatty acids for hemisynthesis. M. 
tuberculosis DAT and TAT were purified following the method described in [178] for the 
purification of Ac2SGL. DAT and TAT were eluted with Ac3SGL and Ac4SGL. The mix of 
lipidic compounds (127.4 mg) obtained were ethanolysed in a solution of sodium ethanolate 
(0.2 M) in ethanol/petroleum ether (1:2, vol) at room temperature for 20 hr. The reaction 
mixture was acidified with HCl solution (1 M) until pH 1.0, and the fatty esters were 
extracted with ethyl acetate/petroleum ether (1:4, vol) four times. The combined organic 
extracts were washed with water and dried over anhydrous magnesium sulfate. The solvent 
was removed and 107.3 mg of esters were obtained. All these compounds were separated by 
“flash” column chromatography eluted with petroleum ether/ether/acetic acid (9:1:0.1, 200 
mL; 8.5:1.5:0.1, 100 mL; 8:2:0.2, 100 mL). The first fractions contained multimethylated non 
hydroxylated fatty esters (6 mg), then a mix with linear ones is eluted (69 mg) and after there 
were the multimethylated hydroxylated ones (3 mg). The first were pooled and saponified 
with 10 eq. of KOH in ethanol/water (3:2, vol) at 80°C overnight. The reaction was acidified 
with an HCl solution (1 M), acids were extracted with ether and the solvent was evaporated 
(5 mg). Then the corresponding SGL4 was synthesized following the general strategy 
depicted in the (Figure 29). 
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 Synthesis of multimethylated fatty acids. Saturated and α,β-unsaturated dextrogyre 
mono-, di-, tri-, and tetramethyl-branched fatty acids and the unsaturated pentamethyl-
branched fatty acid were synthesized following two different methods. The first one involves 
an iterative six-step sequence for the introduction of each branched-methyl group [521]. 
Although resulting in products of very high optical purity, the overall efficiency of this 
procedure is poor, and could not be used for the synthesis of acids with more than 3 
asymmetric carbon atoms. A more efficient method, based on the asymmetric alkylation of 
SAMP-derived hydrazone enolates with alkyl-iodides [522], was used for the synthesis of the 
different multimethyl-branched saturated and α,β-unsaturated fatty acids (data not shown). 
 
 Analysis of shCD1b protein:SGL complexes by IEF. Lipid loading onto shCD1b 
was measured as described in [133]. Briefly, 10-20 µM of LysC-treated shCD1b and 100 µM 
of the sulfoglycolipid were shaken at 600 rpm for 1 hr at 37°C in a solution containing 50 
mM Na acetate / 50 mM NaCl / 1 mM DTT / 1 mM EDTA at pH 4.0. After 6 hr the solution 
was cooled on ice, 2 µL were loaded onto the IEF 4-6.5 gel (Amersham Biosciences). A 
second aliquot of 1-2 µL was withdrawn for cIEF analysis (see below). Incubation in the 
presence of taurocholate (10 mM final conc.) was carried out similarly, with the exception 
that the pH of the solution was adjusted to 5.0 and the incubation time was reduced to 1 hr. 
Isoelectric-focusing electrophoresis (IEF) was performed in a PhastGel system (Amersham 
Biosciences) for 600 accumulated Volt hours (AVh). Protein bands were detected by staining 
with Coomassie R 350. 
 
 Generation of shCD1b and in vitro SGL binding assays. The extracellular soluble 
domain of human CD1b expressed in mouse cells, was purified by anti-CD1b affinity 
chromatography as described in [133]. To reduce the extent of uncontrolled proteolysis of the 
C-terminal extension BirA tag, the last 18 residues of shCD1b were removed by treatment 
with the endoprotease LysC. This preparation was then incubated with natural Ac2SGL or 
synthetic SGL analogs at 37°C and pH 4.0 for 6 hr. In parallel experiments, Ac2SGL or SGL 
were mixed with the mild taurocholate detergent at above CMC concentrations, and then 
incubated with shCD1b for 1 hr at 37°C and pH 5.0. The binding of Ac2SGL or synthetic 
SGL to sCD1b proteins was monitored by isoelectric-focusing electrophoresis (IEF) in gel or 
by capillary electrophoresis (cIEF). 
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 Capillary isoelectrofocusing (cIEF). The ProteomLabTM Capillary Isoelectric 
Focusing Kit (Beckman Coulter, Inc., Fullerton, CA) was used. It contains a neutral coated 
capillary, cIEF gel, ampholytes and protein standard markers. CE separations were performed 
on a ProteomeLab PA 800 System (Beckman Coulter, Inc., Fullerton, CA) with UV detection 
and neutral coated capillary, 50 µm ID x 30.2 cm (20 cm effective length to detector), was 
used for separations. Anolyte was 100 mM H3PO4 in cIEF gel (polymeric solution) and 
catholyte was 20 mM NaOH in water. An aliquot of 1-2 µL sample (prepared for IEF/gel) 
was mixed with 0.9 µL ampholyte 3-10 and 0.5 µL carbonic anhydrase 0.4 mg/mL (pI 5.9) in 
50 µL cIEF gel. After filling the capillary with a sample/ampholyte mixture at 30 psi for 1.5 
min, focusing was performed by applying a constant voltage of 15 kV for 6 min with normal 
polarity and 0.7 psi pressure both at the anode and cathode side. The mobilisation step was 
completed after 30 min at 21 kV by applying 0.7 psi pressure at the anode side. During 
separation, the capillary temperature was maintained at 20°C, CD1b and CD1b:lipid 
complexes were detected at 280 nm [523, 524]. 
 
 Cloning, expression and purification of SCP-2 and hTAP. Oligonucleotide primers 
were synthesized based on the genomic SCP-2 sequence with a sense oligonucleotide primer 
(5’-CCCATGGGAAGCTCTGCAAGTGATGGA-3’) and an antisense oligonucleotide 
primer (5’-AGGATCCGAGCTTAGCGTTGCCTGGC-3’) (Operon Biotechnologies, 
Cologne, Germany). PCR was carried out by using the Advantage HF 2 PCR Kit (Clontech, 
Mountain View, CA) in a GeneAmp PCR System 9600 (Perkin-Elmer, Waltham, MA), with 
human spleen cDNA as a template. PCR conditions were: denaturation for 60 s at 94°C, and 
then 30 cycles under the following conditions: 20 s at 94°C, 30 s at 56°C, 90 s at 68°C. The 
resulting PCR product was purified with the QIAquick Gel Extraction Kit (Qiagen, Basel, 
Switzerland), subcloned into the pCR 2.1-TOPO vector (Invitrogen, Basel, Switzerland) and 
transformed in TOP 10 competent E. coli (Invitrogen). Clones were sequenced using M13 
forward and reverse oligonucleotide primers (Microsynth, Balgach, Switzerland), and 
sequence analysis was done using MacVector. Purification of the plasmid was done using the 
NucleoSpin Plasmid Kit (Macherey-Nagel, Düren, Germany). SCP-2 coding sequence was 
removed from pCR 2.1-TOPO using Nco I and BamH I, and subcloned into the pQE-60 
vector (Qiagen), which contains the 6xHis-tag coding sequence. The pQE-60 vector 
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containing SCP-2 fused in-frame with the C-terminal 6xHis tag sequence was then 
transformed in BL21(DE3)pLysS E. coli bacterial strain (Promega, Madison, WI) for 
production. BL21(DE3)pLysS containing the construct were expanded at 37°C in LB broth 
(Difco Laboratories, Detroit, MI) + 100 µg/mL ampicillin (Sigma-Aldrich, Buchs, 
Switzerland) until OD600 reaches 0.4-0.6. Transcription was then induced using 1 mM IPTG 
(Applichem GmbH, Darmstadt, Germany) and the bacterial pellet was collected 5 hr after 
induction. The pellet was resuspended in PBS 10 mM pH 7.5 and cells were lysed by 
sonication. Supernatant was collected after centrifugation and SCP-2 was purified using HIS-
SelectTM Spin Columns (Sigma-Aldrich). 
The N-terminal 6xHis hTAP is a gift from JM Zingg (Tufts University, Boston, MA) and was 
cloned, produced and purified as previously described [525]. 
 
 Generation of shCD1b:SGL12 dimers. 5 µM of shCD1b and 1 µM of mouse anti-
BirA monoclonal antibody were incubated for 15 min at room temperature, then with 100 µM 
of SGL12, all in a solution containing 50 mM Na acetate / 50 mM NaCl / 1 mM DTT / 1 mM 
EDTA at pH 5.0. The mixture was shaken at 400 rpm for 1 hr at 37°C, then kept at 37°C for 
additional 3 hrs without shaking. Dimers are stable at +4°C for at least one week. 
 
 Flow Cytometry. shCD1b:SGL12 dimers were detected using goat anti-mouse 
IgG2b-RPE mAb (SBA, Birmingham, AL). Cells were stained with combinations of the 
following mAb conjugates, B220/Mac-PB (BioLegend, San Diego, CA), anti-TCRβ-
AlexaFluor (H57-597), CD4/CD8-biotin (BioLegend), SAV-APC (Invitrogen). Samples were 
passed on a CyAn ADP flow cytometer (DakoCytomation, Baar, Switzerland), gated to 
exclude nonviable cells on the basis of light scatter and incorporation of propidium iodide. 
Data were analysed using Summit 4.3 software (DakoCytomation). 
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APPENDIX 
 
 
 Work discussed in the present thesis 
 
Mycolic acids constitute a scaffold for mycobacterial lipidic 
antigens stimulating CD1b-restricted T cells 
 
Collmann A, Layre E, Bastian M, Mariotti S, Czaplicki J, Prandi J, Mori L, 
Stenger S, De Libero G, Puzo G, Gilleron M. 
 These results have been accepted for publication in Chemistry & Biology. 
 
 
Fatty acyl structures of Mycobacterium tuberculosis 
sulfoglycolipid govern T cell immunogenicity 
 
 Collmann A, Guiard J, Garcia-Alles LF, Mourey L, Brando T, Mori L, Gilleron 
M, Prandi J, De Libero G, Puzo G. 
 These results have been submitted to the Journal of Immunology. 
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